"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","characteristics_ch1.7","characteristics_ch1.8","characteristics_ch1.9","characteristics_ch1.10","characteristics_ch1.11","characteristics_ch1.12","characteristics_ch1.13","characteristics_ch1.14","characteristics_ch1.15","characteristics_ch1.16","characteristics_ch1.17","characteristics_ch1.18","characteristics_ch1.19","characteristics_ch1.20","characteristics_ch1.21","characteristics_ch1.22","characteristics_ch1.23","characteristics_ch1.24","characteristics_ch1.25","characteristics_ch1.26","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_phone","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","relation","relation.1","age:ch1","Angioinv:ch1","AOL_os_10y:ch1","e.dmfs:ch1","e.os:ch1","e.rfs:ch1","e.tdm:ch1","er:ch1","filename:ch1","grade:ch1","Histtype:ch1","hospital:ch1","id:ch1","Lymp_infil:ch1","node:ch1","NPI:ch1","risk_AOL:ch1","risknpi:ch1","risksg:ch1","samplename:ch1","size:ch1","Surgery_type:ch1","t.dmfs:ch1","t.os:ch1","t.rfs:ch1","t.tdm:ch1","veridex_risk:ch1"
"GSM177885","VDXGUYU_4002","GSM177885","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4002","Homo sapiens","samplename: VDXGUYU_4002","id: 4002","filename: 10-4002_GUYA.CEL.gz","hospital: GUY","age: 57","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 723","e.rfs: 1","t.os: 937","e.os: 1","t.dmfs: 723","e.dmfs: 1","t.tdm: 723","e.tdm: 1","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 62.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177885/suppl/GSM177885.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","57","1","62.7","1","1","1","1","0","10-4002_GUYA.CEL.gz","3","1","GUY","4002","2","0","4.6","1","2","2","VDXGUYU_4002","3","0","723","937","723","723","Poor"
"GSM177886","VDXGUYU_4008","GSM177886","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4008","Homo sapiens","samplename: VDXGUYU_4008","id: 4008","filename: 26-4008_GUYA.CEL.gz","hospital: GUY","age: 57","size: 3","Surgery_type: 0","Histtype: 2","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 183","e.rfs: 1","t.os: 6591","e.os: 0","t.dmfs: 6591","e.dmfs: 0","t.tdm: 6591","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 69","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177886/suppl/GSM177886.cel.gz","22283","Reanalyzed by: GSE47561","","57","1","69","0","0","1","0","1","26-4008_GUYA.CEL.gz","3","2","GUY","4008","3","0","4.6","1","2","2","VDXGUYU_4008","3","0","6591","6591","183","6591","Poor"
"GSM177887","VDXGUYU_4011","GSM177887","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4011","Homo sapiens","samplename: VDXGUYU_4011","id: 4011","filename: 6-4011_GUYA.CEL.gz","hospital: GUY","age: 48","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 524","e.rfs: 1","t.os: 922","e.os: 1","t.dmfs: 524","e.dmfs: 1","t.tdm: 524","e.tdm: 1","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 66.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177887/suppl/GSM177887.cel.gz","22283","Reanalyzed by: GSE47561","","48","0","66.2","1","1","1","1","0","6-4011_GUYA.CEL.gz","3","1","GUY","4011","2","0","4.5","1","2","2","VDXGUYU_4011","2.5","1","524","922","524","524","Poor"
"GSM177888","VDXGUYU_4014","GSM177888","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4014","Homo sapiens","samplename: VDXGUYU_4014","id: 4014","filename: 9-4014_GUYA.CEL.gz","hospital: GUY","age: 42","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 2192","e.rfs: 1","t.os: 6255","e.os: 1","t.dmfs: 6255","e.dmfs: 1","t.tdm: 6255","e.tdm: 0","risksg: 2","NPI: 4.36","risknpi: 2","AOL_os_10y: 84.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177888/suppl/GSM177888.cel.gz","22283","Reanalyzed by: GSE47561","","42","1","84.9","1","1","1","0","1","9-4014_GUYA.CEL.gz","3","1","GUY","4014","3","0","4.36","1","2","2","VDXGUYU_4014","1.8","0","6255","6255","2192","6255","Poor"
"GSM177889","VDXGUYU_4022","GSM177889","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4022","Homo sapiens","samplename: VDXGUYU_4022","id: 4022","filename: 219-4022_GUYA.CEL.gz","hospital: GUY","age: 46","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 3822","e.rfs: 1","t.os: 4133","e.os: 1","t.dmfs: 3822","e.dmfs: 1","t.tdm: 3822","e.tdm: 1","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 80.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177889/suppl/GSM177889.cel.gz","22283","Reanalyzed by: GSE47561","","46","1","80.2","1","1","1","1","1","219-4022_GUYA.CEL.gz","2","1","GUY","4022","2","0","3.6","1","2","2","VDXGUYU_4022","3","0","3822","4133","3822","3822","Poor"
"GSM177890","VDXGUYU_4033","GSM177890","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4033","Homo sapiens","samplename: VDXGUYU_4033","id: 4033","filename: 17-4033_GUYA.CEL.gz","hospital: GUY","age: 58","size: 2","Surgery_type: 0","Histtype: 2","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 6507","e.rfs: 0","t.os: 6507","e.os: 0","t.dmfs: 6507","e.dmfs: 0","t.tdm: 6507","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 83.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177890/suppl/GSM177890.cel.gz","22283","Reanalyzed by: GSE47561","","58","1","83.1","0","0","0","0","1","17-4033_GUYA.CEL.gz","2","2","GUY","4033","2","0","3.4","1","2","2","VDXGUYU_4033","2","0","6507","6507","6507","6507","Good"
"GSM177891","VDXGUYU_4034","GSM177891","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4034","Homo sapiens","samplename: VDXGUYU_4034","id: 4034","filename: 16-4034_GUYA.CEL.gz","hospital: GUY","age: 44","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 709","e.rfs: 1","t.os: 5947","e.os: 0","t.dmfs: 5947","e.dmfs: 0","t.tdm: 5947","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 80.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177891/suppl/GSM177891.cel.gz","22283","Reanalyzed by: GSE47561","","44","1","80.6","0","0","1","0","0","16-4034_GUYA.CEL.gz","3","1","GUY","4034","3","0","4.4","1","2","2","VDXGUYU_4034","2","1","5947","5947","709","5947","Poor"
"GSM177892","VDXGUYU_4036","GSM177892","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4036","Homo sapiens","samplename: VDXGUYU_4036","id: 4036","filename: 24-4036_GUYA.CEL.gz","hospital: GUY","age: 58","size: 2.5","Surgery_type: 1","Histtype: 2","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 5816","e.rfs: 1","t.os: 5816","e.os: 1","t.dmfs: 5816","e.dmfs: 1","t.tdm: 5816","e.tdm: 0","risksg: 2","NPI: 2.5","risknpi: 1","AOL_os_10y: 82.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177892/suppl/GSM177892.cel.gz","22283","Reanalyzed by: GSE47561","","58","1","82.1","1","1","1","0","1","24-4036_GUYA.CEL.gz","1","2","GUY","4036","2","0","2.5","1","1","2","VDXGUYU_4036","2.5","1","5816","5816","5816","5816","Good"
"GSM177893","VDXGUYU_4040","GSM177893","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4040","Homo sapiens","samplename: VDXGUYU_4040","id: 4040","filename: 13-4040_GUYA.CEL.gz","hospital: GUY","age: 47","size: 3","Surgery_type: 0","Histtype: 2","Angioinv: 2","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 6007","e.rfs: 0","t.os: 6007","e.os: 0","t.dmfs: 6007","e.dmfs: 0","t.tdm: 6007","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 73.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177893/suppl/GSM177893.cel.gz","22283","Reanalyzed by: GSE47561","","47","2","73.2","0","0","0","0","1","13-4040_GUYA.CEL.gz","3","2","GUY","4040","NA","0","4.6","1","2","2","VDXGUYU_4040","3","0","6007","6007","6007","6007","Poor"
"GSM177894","VDXGUYU_4041","GSM177894","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4041","Homo sapiens","samplename: VDXGUYU_4041","id: 4041","filename: 5-4041_GUYA.CEL.gz","hospital: GUY","age: 38","size: 2.5","Surgery_type: 0","Histtype: 2","Angioinv: 2","Lymp_infil: 3","node: 0","grade: 2","er: 1","t.rfs: 422","e.rfs: 1","t.os: 1484","e.os: 1","t.dmfs: 1233","e.dmfs: 1","t.tdm: 1233","e.tdm: 1","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 81.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177894/suppl/GSM177894.cel.gz","22283","Reanalyzed by: GSE47561","","38","2","81.5","1","1","1","1","1","5-4041_GUYA.CEL.gz","2","2","GUY","4041","3","0","3.5","1","2","2","VDXGUYU_4041","2.5","0","1233","1484","422","1233","Poor"
"GSM177895","VDXGUYU_4043","GSM177895","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4043","Homo sapiens","samplename: VDXGUYU_4043","id: 4043","filename: 2-4043_GUYA.CEL.gz","hospital: GUY","age: 59","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 1","t.rfs: 1136","e.rfs: 1","t.os: 1911","e.os: 1","t.dmfs: 1136","e.dmfs: 1","t.tdm: 1136","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 77.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177895/suppl/GSM177895.cel.gz","22283","Reanalyzed by: GSE47561","","59","1","77.8","1","1","1","1","1","2-4043_GUYA.CEL.gz","3","1","GUY","4043","2","0","4.4","1","2","2","VDXGUYU_4043","2","1","1136","1911","1136","1136","Poor"
"GSM177896","VDXGUYU_4044","GSM177896","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4044","Homo sapiens","samplename: VDXGUYU_4044","id: 4044","filename: 3-4044_GUYA.CEL.gz","hospital: GUY","age: 50","size: 0.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 5984","e.rfs: 0","t.os: 5984","e.os: 0","t.dmfs: 5984","e.dmfs: 0","t.tdm: 5984","e.tdm: 0","risksg: 1","NPI: 2.16","risknpi: 1","AOL_os_10y: 94.3","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177896/suppl/GSM177896.cel.gz","22283","Reanalyzed by: GSE47561","","50","1","94.3","0","0","0","0","1","3-4044_GUYA.CEL.gz","1","1","GUY","4044","1","0","2.16","0","1","1","VDXGUYU_4044","0.8","0","5984","5984","5984","5984","Good"
"GSM177897","VDXGUYU_4045","GSM177897","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4045","Homo sapiens","samplename: VDXGUYU_4045","id: 4045","filename: 22-4045_GUYA.CEL.gz","hospital: GUY","age: 46","size: 4.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 6249","e.rfs: 0","t.os: 6249","e.os: 0","t.dmfs: 6249","e.dmfs: 0","t.tdm: 6249","e.tdm: 0","risksg: 2","NPI: 4.9","risknpi: 2","AOL_os_10y: 62.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177897/suppl/GSM177897.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","46","1","62.7","0","0","0","0","0","22-4045_GUYA.CEL.gz","3","1","GUY","4045","3","0","4.9","1","2","2","VDXGUYU_4045","4.5","0","6249","6249","6249","6249","Poor"
"GSM177898","VDXGUYU_4046","GSM177898","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4046","Homo sapiens","samplename: VDXGUYU_4046","id: 4046","filename: 19-4046_GUYA.CEL.gz","hospital: GUY","age: 57","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 0","t.rfs: 2841","e.rfs: 1","t.os: 4372","e.os: 1","t.dmfs: 4066","e.dmfs: 1","t.tdm: 4066","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 78.3","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177898/suppl/GSM177898.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","57","1","78.3","1","1","1","1","0","19-4046_GUYA.CEL.gz","2","1","GUY","4046","2","0","3.4","1","2","2","VDXGUYU_4046","2","0","4066","4372","2841","4066","Good"
"GSM177899","VDXGUYU_4049","GSM177899","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4049","Homo sapiens","samplename: VDXGUYU_4049","id: 4049","filename: 20-4049_GUYA.CEL.gz","hospital: GUY","age: 33","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 3","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 458","e.rfs: 1","t.os: 977","e.os: 1","t.dmfs: 690","e.dmfs: 1","t.tdm: 690","e.tdm: 1","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 68.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177899/suppl/GSM177899.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","33","3","68.1","1","1","1","1","0","20-4049_GUYA.CEL.gz","3","1","GUY","4049","3","0","4.5","1","2","2","VDXGUYU_4049","2.5","0","690","977","458","690","Good"
"GSM177900","VDXGUYU_4052","GSM177900","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4052","Homo sapiens","samplename: VDXGUYU_4052","id: 4052","filename: 197-4052_GUYA.CEL.gz","hospital: GUY","age: 42","size: 2","Surgery_type: 0","Histtype: 2","Angioinv: NA","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 994","e.rfs: 1","t.os: 3830","e.os: 1","t.dmfs: 994","e.dmfs: 1","t.tdm: 994","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 84.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177900/suppl/GSM177900.cel.gz","22283","Reanalyzed by: GSE47561","","42","NA","84.9","1","1","1","1","1","197-4052_GUYA.CEL.gz","3","2","GUY","4052","1","0","4.4","1","2","2","VDXGUYU_4052","2","0","994","3830","994","994","Poor"
"GSM177901","VDXGUYU_4054","GSM177901","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4054","Homo sapiens","samplename: VDXGUYU_4054","id: 4054","filename: 7-4054_GUYA.CEL.gz","hospital: GUY","age: 38","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 282","e.rfs: 1","t.os: 667","e.os: 1","t.dmfs: 434","e.dmfs: 1","t.tdm: 434","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 81.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177901/suppl/GSM177901.cel.gz","22283","Reanalyzed by: GSE47561","","38","2","81.5","1","1","1","1","0","7-4054_GUYA.CEL.gz","3","1","GUY","4054","2","0","4.4","1","2","2","VDXGUYU_4054","2","0","434","667","282","434","Poor"
"GSM177902","VDXGUYU_4056","GSM177902","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4056","Homo sapiens","samplename: VDXGUYU_4056","id: 4056","filename: 213-4056_GUYA.CEL.gz","hospital: GUY","age: 55","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: 3","Lymp_infil: 2","node: 0","grade: 2","er: 0","t.rfs: 548","e.rfs: 1","t.os: 2129","e.os: 1","t.dmfs: 1743","e.dmfs: 1","t.tdm: 1743","e.tdm: 1","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 65.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177902/suppl/GSM177902.cel.gz","22283","Reanalyzed by: GSE47561","","55","3","65.5","1","1","1","1","0","213-4056_GUYA.CEL.gz","2","1","GUY","4056","2","0","3.5","1","2","2","VDXGUYU_4056","2.5","1","1743","2129","548","1743","Poor"
"GSM177903","VDXGUYU_4060","GSM177903","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4060","Homo sapiens","samplename: VDXGUYU_4060","id: 4060","filename: 8-4060_GUYA.CEL.gz","hospital: GUY","age: 57","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 2","er: 0","t.rfs: 1820","e.rfs: 1","t.os: 3590","e.os: 1","t.dmfs: 2863","e.dmfs: 1","t.tdm: 2863","e.tdm: 1","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 64.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177903/suppl/GSM177903.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","57","1","64.5","1","1","1","1","0","8-4060_GUYA.CEL.gz","2","1","GUY","4060","3","0","3.5","1","2","2","VDXGUYU_4060","2.5","0","2863","3590","1820","2863","Poor"
"GSM177904","VDXGUYU_4061","GSM177904","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4061","Homo sapiens","samplename: VDXGUYU_4061","id: 4061","filename: 209-4061_GUYA.CEL.gz","hospital: GUY","age: 46","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 3","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 5693","e.rfs: 0","t.os: 5693","e.os: 0","t.dmfs: 5693","e.dmfs: 0","t.tdm: 5693","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 80.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177904/suppl/GSM177904.cel.gz","22283","Reanalyzed by: GSE47561","","46","3","80.2","0","0","0","0","1","209-4061_GUYA.CEL.gz","2","1","GUY","4061","2","0","3.5","1","2","2","VDXGUYU_4061","2.5","0","5693","5693","5693","5693","Poor"
"GSM177905","VDXGUYU_4062","GSM177905","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4062","Homo sapiens","samplename: VDXGUYU_4062","id: 4062","filename: 228-4062_GUYA.CEL.gz","hospital: GUY","age: 50","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 3","node: 0","grade: 2","er: 1","t.rfs: 5823","e.rfs: 0","t.os: 5823","e.os: 0","t.dmfs: 5823","e.dmfs: 0","t.tdm: 5823","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 87.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177905/suppl/GSM177905.cel.gz","22283","Reanalyzed by: GSE47561","","50","2","87.6","0","0","0","0","1","228-4062_GUYA.CEL.gz","2","1","GUY","4062","3","0","3.4","1","2","2","VDXGUYU_4062","2","0","5823","5823","5823","5823","Poor"
"GSM177906","VDXGUYU_4067","GSM177906","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4067","Homo sapiens","samplename: VDXGUYU_4067","id: 4067","filename: 207-4067_GUYA.CEL.gz","hospital: GUY","age: 46","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 5785","e.rfs: 0","t.os: 5785","e.os: 0","t.dmfs: 5785","e.dmfs: 0","t.tdm: 5785","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 80.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177906/suppl/GSM177906.cel.gz","22283","Reanalyzed by: GSE47561","","46","1","80.2","0","0","0","0","0","207-4067_GUYA.CEL.gz","3","1","GUY","4067","3","0","4.4","1","2","2","VDXGUYU_4067","2","1","5785","5785","5785","5785","Poor"
"GSM177907","VDXGUYU_4072","GSM177907","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4072","Homo sapiens","samplename: VDXGUYU_4072","id: 4072","filename: 27-4072_GUYA.CEL.gz","hospital: GUY","age: 46","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 5598","e.rfs: 1","t.os: 5661","e.os: 0","t.dmfs: 5661","e.dmfs: 0","t.tdm: 5661","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 80.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177907/suppl/GSM177907.cel.gz","22283","Reanalyzed by: GSE47561","","46","2","80.2","0","0","1","0","1","27-4072_GUYA.CEL.gz","2","1","GUY","4072","2","0","3.5","1","2","2","VDXGUYU_4072","2.5","0","5661","5661","5598","5661","Poor"
"GSM177908","VDXGUYU_4073","GSM177908","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4073","Homo sapiens","samplename: VDXGUYU_4073","id: 4073","filename: 12-4073_GUYA.CEL.gz","hospital: GUY","age: 51","size: 1.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 2909","e.rfs: 1","t.os: 2909","e.os: 1","t.dmfs: 2909","e.dmfs: 1","t.tdm: 2909","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177908/suppl/GSM177908.cel.gz","22283","Reanalyzed by: GSE47561","","51","1","87.2","1","1","1","0","1","12-4073_GUYA.CEL.gz","2","1","GUY","4073","2","0","3.3","1","1","2","VDXGUYU_4073","1.5","0","2909","2909","2909","2909","Poor"
"GSM177909","VDXGUYU_4074","GSM177909","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4074","Homo sapiens","samplename: VDXGUYU_4074","id: 4074","filename: 15-4074_GUYA.CEL.gz","hospital: GUY","age: 58","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: 3","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 121","e.rfs: 1","t.os: 1674","e.os: 1","t.dmfs: 1171","e.dmfs: 1","t.tdm: 1171","e.tdm: 1","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 62.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177909/suppl/GSM177909.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","58","3","62.1","1","1","1","1","0","15-4074_GUYA.CEL.gz","3","1","GUY","4074","3","0","4.5","1","2","2","VDXGUYU_4074","2.5","1","1171","1674","121","1171","Poor"
"GSM177910","VDXGUYU_4075","GSM177910","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4075","Homo sapiens","samplename: VDXGUYU_4075","id: 4075","filename: 23-4075_GUYA.CEL.gz","hospital: GUY","age: 59","size: 2.6","Surgery_type: 0","Histtype: 3","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 5110","e.rfs: 0","t.os: 5110","e.os: 0","t.dmfs: 5110","e.dmfs: 0","t.tdm: 5110","e.tdm: 0","risksg: 2","NPI: 2.52","risknpi: 1","AOL_os_10y: 81.4","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177910/suppl/GSM177910.cel.gz","22283","Reanalyzed by: GSE47561","","59","1","81.4","0","0","0","0","1","23-4075_GUYA.CEL.gz","1","3","GUY","4075","2","0","2.52","1","1","2","VDXGUYU_4075","2.6","0","5110","5110","5110","5110","Good"
"GSM177911","VDXGUYU_4076","GSM177911","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4076","Homo sapiens","samplename: VDXGUYU_4076","id: 4076","filename: 11-4076_GUYA.CEL.gz","hospital: GUY","age: 49","size: 0.6","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 1","t.rfs: 5533","e.rfs: 0","t.os: 5533","e.os: 0","t.dmfs: 5533","e.dmfs: 0","t.tdm: 5533","e.tdm: 0","risksg: 2","NPI: 3.12","risknpi: 1","AOL_os_10y: 92.8","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177911/suppl/GSM177911.cel.gz","22283","Reanalyzed by: GSE47561","","49","1","92.8","0","0","0","0","1","11-4076_GUYA.CEL.gz","2","1","GUY","4076","1","0","3.12","0","1","2","VDXGUYU_4076","0.6","1","5533","5533","5533","5533","Good"
"GSM177912","VDXGUYU_4080","GSM177912","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXGUYU_4080","Homo sapiens","samplename: VDXGUYU_4080","id: 4080","filename: 199-4080_GUYA.CEL.gz","hospital: GUY","age: 43","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 1429","e.rfs: 1","t.os: 5571","e.os: 0","t.dmfs: 5571","e.dmfs: 0","t.tdm: 5571","e.tdm: 0","risksg: 2","NPI: 2.5","risknpi: 1","AOL_os_10y: 88.7","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177912/suppl/GSM177912.cel.gz","22283","","","43","1","88.7","0","0","1","0","1","199-4080_GUYA.CEL.gz","1","1","GUY","4080","1","0","2.5","0","1","2","VDXGUYU_4080","2.5","0","5571","5571","1429","5571","Good"
"GSM177913","VDXGUYU_4081","GSM177913","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4081","Homo sapiens","samplename: VDXGUYU_4081","id: 4081","filename: 25-4081_GUYA.CEL.gz","hospital: GUY","age: 47","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 0","t.rfs: 5519","e.rfs: 0","t.os: 5519","e.os: 0","t.dmfs: 5519","e.dmfs: 0","t.tdm: 5519","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 80","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177913/suppl/GSM177913.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","47","1","80","0","0","0","0","0","25-4081_GUYA.CEL.gz","3","1","GUY","4081","3","0","4.4","1","2","2","VDXGUYU_4081","2","1","5519","5519","5519","5519","Poor"
"GSM177914","VDXGUYU_4087","GSM177914","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4087","Homo sapiens","samplename: VDXGUYU_4087","id: 4087","filename: 18-4087_GUYA.CEL.gz","hospital: GUY","age: 37","size: 1.7","Surgery_type: 1","Histtype: 1","Angioinv: 2","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 5379","e.rfs: 0","t.os: 5379","e.os: 0","t.dmfs: 5379","e.dmfs: 0","t.tdm: 5379","e.tdm: 0","risksg: 2","NPI: 4.34","risknpi: 2","AOL_os_10y: 85.6","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177914/suppl/GSM177914.cel.gz","22283","Reanalyzed by: GSE47561","","37","2","85.6","0","0","0","0","1","18-4087_GUYA.CEL.gz","3","1","GUY","4087","3","0","4.34","1","2","2","VDXGUYU_4087","1.7","1","5379","5379","5379","5379","Good"
"GSM177915","VDXGUYU_4088","GSM177915","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4088","Homo sapiens","samplename: VDXGUYU_4088","id: 4088","filename: 14-4088_GUYA.CEL.gz","hospital: GUY","age: 48","size: 4","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 4675","e.rfs: 0","t.os: 4675","e.os: 0","t.dmfs: 4675","e.dmfs: 0","t.tdm: 4675","e.tdm: 0","risksg: 2","NPI: 4.8","risknpi: 2","AOL_os_10y: 65.2","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177915/suppl/GSM177915.cel.gz","22283","Reanalyzed by: GSE47561","","48","1","65.2","0","0","0","0","1","14-4088_GUYA.CEL.gz","3","1","GUY","4088","3","0","4.8","1","2","2","VDXGUYU_4088","4","0","4675","4675","4675","4675","Good"
"GSM177916","VDXGUYU_4096","GSM177916","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4096","Homo sapiens","samplename: VDXGUYU_4096","id: 4096","filename: 189-4096_GUYA.CEL.gz","hospital: GUY","age: 47","size: 1.9","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 1666","e.rfs: 1","t.os: 4652","e.os: 0","t.dmfs: 4652","e.dmfs: 0","t.tdm: 4652","e.tdm: 0","risksg: 2","NPI: 3.38","risknpi: 2","AOL_os_10y: 88.6","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177916/suppl/GSM177916.cel.gz","22283","Reanalyzed by: GSE47561","","47","1","88.6","0","0","1","0","1","189-4096_GUYA.CEL.gz","2","1","GUY","4096","2","0","3.38","0","2","2","VDXGUYU_4096","1.9","0","4652","4652","1666","4652","Poor"
"GSM177917","VDXGUYU_4097","GSM177917","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4097","Homo sapiens","samplename: VDXGUYU_4097","id: 4097","filename: 200-4097_GUYA.CEL.gz","hospital: GUY","age: 46","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 4227","e.rfs: 0","t.os: 4227","e.os: 0","t.dmfs: 4227","e.dmfs: 0","t.tdm: 4227","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 80.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177917/suppl/GSM177917.cel.gz","22283","Reanalyzed by: GSE47561","","46","1","80.2","0","0","0","0","1","200-4097_GUYA.CEL.gz","2","1","GUY","4097","2","0","3.5","1","2","2","VDXGUYU_4097","2.5","0","4227","4227","4227","4227","Poor"
"GSM177918","VDXGUYU_4098","GSM177918","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4098","Homo sapiens","samplename: VDXGUYU_4098","id: 4098","filename: 4-4098_GUYA.CEL.gz","hospital: GUY","age: 48","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 316","e.rfs: 1","t.os: 1530","e.os: 1","t.dmfs: 910","e.dmfs: 1","t.tdm: 910","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 79.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177918/suppl/GSM177918.cel.gz","22283","Reanalyzed by: GSE47561","","48","2","79.7","1","1","1","1","0","4-4098_GUYA.CEL.gz","3","1","GUY","4098","2","0","4.4","1","2","2","VDXGUYU_4098","2","0","910","1530","316","910","Poor"
"GSM177919","VDXGUYU_4099","GSM177919","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4099","Homo sapiens","samplename: VDXGUYU_4099","id: 4099","filename: 21-4099_GUYA.CEL.gz","hospital: GUY","age: 58","size: 1.9","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 4472","e.rfs: 0","t.os: 4472","e.os: 0","t.dmfs: 4472","e.dmfs: 0","t.tdm: 4472","e.tdm: 0","risksg: 2","NPI: 3.38","risknpi: 2","AOL_os_10y: 83.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177919/suppl/GSM177919.cel.gz","22283","Reanalyzed by: GSE47561","","58","1","83.1","0","0","0","0","1","21-4099_GUYA.CEL.gz","2","1","GUY","4099","2","0","3.38","1","2","2","VDXGUYU_4099","1.9","0","4472","4472","4472","4472","Good"
"GSM177920","VDXGUYU_4105","GSM177920","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXGUYU_4105","Homo sapiens","samplename: VDXGUYU_4105","id: 4105","filename: 1-4105_GUYA.CEL.gz","hospital: GUY","age: 34","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 350","e.rfs: 1","t.os: 1275","e.os: 1","t.dmfs: 1206","e.dmfs: 1","t.tdm: 1206","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 79.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177920/suppl/GSM177920.cel.gz","22283","Reanalyzed by: GSE47561","","34","1","79.9","1","1","1","1","1","1-4105_GUYA.CEL.gz","3","1","GUY","4105","1","0","4.4","1","2","2","VDXGUYU_4105","2","0","1206","1275","350","1206","Poor"
"GSM177921","VDXIGRU_166154","GSM177921","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_166154","Homo sapiens","samplename: VDXIGRU_166154","id: 166154","filename: 233-166154_IGRA.CEL.gz","hospital: IGR","age: 30","size: 4.5","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 1","t.rfs: 5632","e.rfs: 1","t.os: 7057","e.os: 0","t.dmfs: 7057","e.dmfs: 0","t.tdm: 7057","e.tdm: 0","risksg: 2","NPI: 3.9","risknpi: 2","AOL_os_10y: 65.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177921/suppl/GSM177921.cel.gz","22283","Reanalyzed by: GSE47561","","30","1","65.3","0","0","1","0","1","233-166154_IGRA.CEL.gz","2","1","IGR","166154","1","0","3.9","1","2","2","VDXIGRU_166154","4.5","1","7057","7057","5632","7057","Poor"
"GSM177922","VDXIGRU_171150","GSM177922","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_171150","Homo sapiens","samplename: VDXIGRU_171150","id: 171150","filename: 68-171150_IGRA.CEL.gz","hospital: IGR","age: 35","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 958","e.rfs: 0","t.os: 958","e.os: 0","t.dmfs: 958","e.dmfs: 0","t.tdm: 958","e.tdm: 0","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 81.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177922/suppl/GSM177922.cel.gz","22283","Reanalyzed by: GSE47561","","35","1","81.8","0","0","0","0","1","68-171150_IGRA.CEL.gz","2","1","IGR","171150","2","0","3.6","1","2","2","VDXIGRU_171150","3","1","958","958","958","958","Good"
"GSM177923","VDXIGRU_171260","GSM177923","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_171260","Homo sapiens","samplename: VDXIGRU_171260","id: 171260","filename: 30-171260_IGRA.CEL.gz","hospital: IGR","age: 56","size: 2.6","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 5359","e.rfs: 0","t.os: 5359","e.os: 0","t.dmfs: 5359","e.dmfs: 0","t.tdm: 5359","e.tdm: 0","risksg: 2","NPI: 4.52","risknpi: 2","AOL_os_10y: 63.2","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177923/suppl/GSM177923.cel.gz","22283","Reanalyzed by: GSE47561","","56","1","63.2","0","0","0","0","0","30-171260_IGRA.CEL.gz","3","1","IGR","171260","2","0","4.52","1","2","2","VDXIGRU_171260","2.6","0","5359","5359","5359","5359","Good"
"GSM177924","VDXIGRU_171558","GSM177924","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_171558","Homo sapiens","samplename: VDXIGRU_171558","id: 171558","filename: 47-171558_IGRA.CEL.gz","hospital: IGR","age: 35","size: 3.2","Surgery_type: 1","Histtype: 8","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 0","t.rfs: 5945","e.rfs: 0","t.os: 5945","e.os: 0","t.dmfs: 5945","e.dmfs: 0","t.tdm: 5945","e.tdm: 0","risksg: 2","NPI: 3.64","risknpi: 2","AOL_os_10y: 66.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177924/suppl/GSM177924.cel.gz","22283","Reanalyzed by: GSE47561","","35","1","66.1","0","0","0","0","0","47-171558_IGRA.CEL.gz","2","8","IGR","171558","1","0","3.64","1","2","2","VDXIGRU_171558","3.2","1","5945","5945","5945","5945","Good"
"GSM177925","VDXIGRU_171620","GSM177925","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_171620","Homo sapiens","samplename: VDXIGRU_171620","id: 171620","filename: 178-171620_IGRA.CEL.gz","hospital: IGR","age: 52","size: 2.7","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 0","t.rfs: 5651","e.rfs: 0","t.os: 5651","e.os: 0","t.dmfs: 5651","e.dmfs: 0","t.tdm: 5651","e.tdm: 0","risksg: 2","NPI: 4.54","risknpi: 2","AOL_os_10y: 64.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177925/suppl/GSM177925.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","52","1","64.9","0","0","0","0","0","178-171620_IGRA.CEL.gz","3","1","IGR","171620","1","0","4.54","1","2","2","VDXIGRU_171620","2.7","1","5651","5651","5651","5651","Poor"
"GSM177926","VDXIGRU_172086","GSM177926","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_172086","Homo sapiens","samplename: VDXIGRU_172086","id: 172086","filename: 192-172086_IGRA.CEL.gz","hospital: IGR","age: 47","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 1","t.rfs: 528","e.rfs: 1","t.os: 6036","e.os: 1","t.dmfs: 528","e.dmfs: 1","t.tdm: 528","e.tdm: 1","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 73.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177926/suppl/GSM177926.cel.gz","22283","Reanalyzed by: GSE47561","","47","1","73.2","1","1","1","1","1","192-172086_IGRA.CEL.gz","3","1","IGR","172086","2","0","4.6","1","2","2","VDXIGRU_172086","3","0","528","6036","528","528","Poor"
"GSM177927","VDXIGRU_211980","GSM177927","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_211980","Homo sapiens","samplename: VDXIGRU_211980","id: 211980","filename: 70-211980_IGRA.CEL.gz","hospital: IGR","age: 42","size: 1.6","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 408","e.rfs: 1","t.os: 1436","e.os: 1","t.dmfs: 796","e.dmfs: 1","t.tdm: 796","e.tdm: 1","risksg: 2","NPI: 4.32","risknpi: 2","AOL_os_10y: 81","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177927/suppl/GSM177927.cel.gz","22283","Reanalyzed by: GSE47561","","42","1","81","1","1","1","1","0","70-211980_IGRA.CEL.gz","3","1","IGR","211980","2","0","4.32","1","2","2","VDXIGRU_211980","1.6","0","796","1436","408","796","Poor"
"GSM177928","VDXIGRU_214603","GSM177928","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_214603","Homo sapiens","samplename: VDXIGRU_214603","id: 214603","filename: 31-214603_IGRA.CEL.gz","hospital: IGR","age: 54","size: 1.7","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 5685","e.rfs: 0","t.os: 5685","e.os: 0","t.dmfs: 5685","e.dmfs: 0","t.tdm: 5685","e.tdm: 0","risksg: 2","NPI: 3.34","risknpi: 2","AOL_os_10y: 85.7","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177928/suppl/GSM177928.cel.gz","22283","Reanalyzed by: GSE47561","","54","1","85.7","0","0","0","0","1","31-214603_IGRA.CEL.gz","2","1","IGR","214603","2","0","3.34","1","2","2","VDXIGRU_214603","1.7","0","5685","5685","5685","5685","Good"
"GSM177929","VDXIGRU_216806","GSM177929","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_216806","Homo sapiens","samplename: VDXIGRU_216806","id: 216806","filename: 33-216806_IGRA.CEL.gz","hospital: IGR","age: 42","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 1023","e.rfs: 1","t.os: 1754","e.os: 1","t.dmfs: 1023","e.dmfs: 1","t.tdm: 1023","e.tdm: 1","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 74.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177929/suppl/GSM177929.cel.gz","22283","Reanalyzed by: GSE47561","","42","1","74.2","1","1","1","1","1","33-216806_IGRA.CEL.gz","3","1","IGR","216806","1","0","4.5","1","2","2","VDXIGRU_216806","2.5","0","1023","1754","1023","1023","Poor"
"GSM177930","VDXIGRU_216939","GSM177930","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_216939","Homo sapiens","samplename: VDXIGRU_216939","id: 216939","filename: 58-216939_IGRA.CEL.gz","hospital: IGR","age: 50","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 4791","e.rfs: 0","t.os: 4791","e.os: 0","t.dmfs: 4791","e.dmfs: 0","t.tdm: 4791","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 79","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177930/suppl/GSM177930.cel.gz","22283","Reanalyzed by: GSE47561","","50","1","79","0","0","0","0","1","58-216939_IGRA.CEL.gz","2","1","IGR","216939","2","0","3.5","1","2","2","VDXIGRU_216939","2.5","0","4791","4791","4791","4791","Good"
"GSM177931","VDXIGRU_217320","GSM177931","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_217320","Homo sapiens","samplename: VDXIGRU_217320","id: 217320","filename: 36-217320_IGRA.CEL.gz","hospital: IGR","age: 42","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 1215","e.rfs: 0","t.os: 1215","e.os: 0","t.dmfs: 1215","e.dmfs: 0","t.tdm: 1215","e.tdm: 0","risksg: 2","NPI: 2.6","risknpi: 1","AOL_os_10y: 88.9","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177931/suppl/GSM177931.cel.gz","22283","Reanalyzed by: GSE47561","","42","1","88.9","0","0","0","0","1","36-217320_IGRA.CEL.gz","1","1","IGR","217320","2","0","2.6","0","1","2","VDXIGRU_217320","3","1","1215","1215","1215","1215","Poor"
"GSM177932","VDXIGRU_219139","GSM177932","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219139","Homo sapiens","samplename: VDXIGRU_219139","id: 219139","filename: 202-219139_IGRA.CEL.gz","hospital: IGR","age: 38","size: 3.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 3779","e.rfs: 0","t.os: 3779","e.os: 0","t.dmfs: 3779","e.dmfs: 0","t.tdm: 3779","e.tdm: 0","risksg: 2","NPI: 2.7","risknpi: 1","AOL_os_10y: 84.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177932/suppl/GSM177932.cel.gz","22283","Reanalyzed by: GSE47561","","38","1","84.5","0","0","0","0","1","202-219139_IGRA.CEL.gz","1","1","IGR","219139","2","0","2.7","1","1","2","VDXIGRU_219139","3.5","0","3779","3779","3779","3779","Poor"
"GSM177933","VDXIGRU_219468","GSM177933","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219468","Homo sapiens","samplename: VDXIGRU_219468","id: 219468","filename: 61-219468_IGRA.CEL.gz","hospital: IGR","age: 37","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 5306","e.rfs: 0","t.os: 5306","e.os: 0","t.dmfs: 5306","e.dmfs: 0","t.tdm: 5306","e.tdm: 0","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 74.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177933/suppl/GSM177933.cel.gz","22283","Reanalyzed by: GSE47561","","37","1","74.7","0","0","0","0","1","61-219468_IGRA.CEL.gz","3","1","IGR","219468","1","0","4.5","1","2","2","VDXIGRU_219468","2.5","0","5306","5306","5306","5306","Poor"
"GSM177934","VDXIGRU_219490","GSM177934","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219490","Homo sapiens","samplename: VDXIGRU_219490","id: 219490","filename: 52-219490_IGRA.CEL.gz","hospital: IGR","age: 44","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 5678","e.rfs: 0","t.os: 5678","e.os: 0","t.dmfs: 5678","e.dmfs: 0","t.tdm: 5678","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 73.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177934/suppl/GSM177934.cel.gz","22283","Reanalyzed by: GSE47561","","44","1","73.8","0","0","0","0","1","52-219490_IGRA.CEL.gz","3","1","IGR","219490","3","0","4.6","1","2","2","VDXIGRU_219490","3","1","5678","5678","5678","5678","Poor"
"GSM177935","VDXIGRU_219587","GSM177935","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219587","Homo sapiens","samplename: VDXIGRU_219587","id: 219587","filename: 240-219587_IGRA.CEL.gz","hospital: IGR","age: 37","size: 3.1","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 421","e.rfs: 1","t.os: 794","e.os: 1","t.dmfs: 421","e.dmfs: 1","t.tdm: 421","e.tdm: 1","risksg: 2","NPI: 4.62","risknpi: 2","AOL_os_10y: 63.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177935/suppl/GSM177935.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","37","1","63.9","1","1","1","1","0","240-219587_IGRA.CEL.gz","3","1","IGR","219587","2","0","4.62","1","2","2","VDXIGRU_219587","3.1","0","421","794","421","421","Poor"
"GSM177936","VDXIGRU_219863","GSM177936","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219863","Homo sapiens","samplename: VDXIGRU_219863","id: 219863","filename: 35-219863_IGRA.CEL.gz","hospital: IGR","age: 51","size: 1.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 840","e.rfs: 1","t.os: 5612","e.os: 0","t.dmfs: 5612","e.dmfs: 0","t.tdm: 5612","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177936/suppl/GSM177936.cel.gz","22283","Reanalyzed by: GSE47561","","51","1","87.2","0","0","1","0","1","35-219863_IGRA.CEL.gz","2","1","IGR","219863","2","0","3.3","1","1","2","VDXIGRU_219863","1.5","0","5612","5612","840","5612","Good"
"GSM177937","VDXIGRU_219873","GSM177937","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_219873","Homo sapiens","samplename: VDXIGRU_219873","id: 219873","filename: 37-219873_IGRA.CEL.gz","hospital: IGR","age: 53","size: 4","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 3121","e.rfs: 1","t.os: 3326","e.os: 0","t.dmfs: 3121","e.dmfs: 1","t.tdm: 3121","e.tdm: 1","risksg: 2","NPI: 4.8","risknpi: 2","AOL_os_10y: 60.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177937/suppl/GSM177937.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","53","NA","60.8","1","0","1","1","0","37-219873_IGRA.CEL.gz","3","1","IGR","219873","NA","0","4.8","1","2","2","VDXIGRU_219873","4","1","3121","3326","3121","3121","Good"
"GSM177938","VDXIGRU_245392","GSM177938","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_245392","Homo sapiens","samplename: VDXIGRU_245392","id: 245392","filename: 39-245392_IGRA.CEL.gz","hospital: IGR","age: 49","size: 2.5","Surgery_type: 0","Histtype: 7","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 1104","e.rfs: 0","t.os: 1104","e.os: 0","t.dmfs: 1104","e.dmfs: 0","t.tdm: 1104","e.tdm: 0","risksg: 2","NPI: 2.5","risknpi: 1","AOL_os_10y: 87","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177938/suppl/GSM177938.cel.gz","22283","Reanalyzed by: GSE47561","","49","1","87","0","0","0","0","1","39-245392_IGRA.CEL.gz","1","7","IGR","245392","2","0","2.5","1","1","2","VDXIGRU_245392","2.5","0","1104","1104","1104","1104","Good"
"GSM177939","VDXIGRU_245596","GSM177939","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_245596","Homo sapiens","samplename: VDXIGRU_245596","id: 245596","filename: 208-245596_IGRA.CEL.gz","hospital: IGR","age: 43","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 0","t.rfs: 4691","e.rfs: 0","t.os: 4691","e.os: 0","t.dmfs: 4691","e.dmfs: 0","t.tdm: 4691","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 67.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177939/suppl/GSM177939.cel.gz","22283","Reanalyzed by: GSE47561","","43","1","67.1","0","0","0","0","0","208-245596_IGRA.CEL.gz","3","1","IGR","245596","2","0","4.6","1","2","2","VDXIGRU_245596","3","1","4691","4691","4691","4691","Good"
"GSM177940","VDXIGRU_246047","GSM177940","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246047","Homo sapiens","samplename: VDXIGRU_246047","id: 246047","filename: 42-246047_IGRA.CEL.gz","hospital: IGR","age: 39","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 1609","e.rfs: 1","t.os: 5238","e.os: 0","t.dmfs: 5238","e.dmfs: 0","t.tdm: 5238","e.tdm: 0","risksg: 2","NPI: 3.44","risknpi: 2","AOL_os_10y: 81.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177940/suppl/GSM177940.cel.gz","22283","Reanalyzed by: GSE47561","","39","2","81.4","0","0","1","0","1","42-246047_IGRA.CEL.gz","2","1","IGR","246047","2","0","3.44","1","2","2","VDXIGRU_246047","2.2","0","5238","5238","1609","5238","Poor"
"GSM177941","VDXIGRU_246166","GSM177941","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246166","Homo sapiens","samplename: VDXIGRU_246166","id: 246166","filename: 239-246166_IGRA.CEL.gz","hospital: IGR","age: 47","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 1","t.rfs: 5101","e.rfs: 0","t.os: 5101","e.os: 0","t.dmfs: 5101","e.dmfs: 0","t.tdm: 5101","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 88.6","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177941/suppl/GSM177941.cel.gz","22283","Reanalyzed by: GSE47561","","47","1","88.6","0","0","0","0","1","239-246166_IGRA.CEL.gz","2","1","IGR","246166","1","0","3.4","0","2","2","VDXIGRU_246166","2","0","5101","5101","5101","5101","Poor"
"GSM177942","VDXIGRU_246381","GSM177942","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246381","Homo sapiens","samplename: VDXIGRU_246381","id: 246381","filename: 45-246381_IGRA.CEL.gz","hospital: IGR","age: 42","size: 1.9","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 1","t.rfs: 2809","e.rfs: 0","t.os: 2809","e.os: 0","t.dmfs: 2809","e.dmfs: 0","t.tdm: 2809","e.tdm: 0","risksg: 2","NPI: 4.38","risknpi: 2","AOL_os_10y: 84.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177942/suppl/GSM177942.cel.gz","22283","Reanalyzed by: GSE47561","","42","1","84.9","0","0","0","0","1","45-246381_IGRA.CEL.gz","3","1","IGR","246381","2","0","4.38","1","2","2","VDXIGRU_246381","1.9","0","2809","2809","2809","2809","Poor"
"GSM177943","VDXIGRU_246560","GSM177943","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246560","Homo sapiens","samplename: VDXIGRU_246560","id: 246560","filename: 185-246560_IGRA.CEL.gz","hospital: IGR","age: 39","size: 1.2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 0","t.rfs: 3296","e.rfs: 0","t.os: 3296","e.os: 0","t.dmfs: 3296","e.dmfs: 0","t.tdm: 3296","e.tdm: 0","risksg: 2","NPI: 3.24","risknpi: 1","AOL_os_10y: 84.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177943/suppl/GSM177943.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","39","1","84.4","0","0","0","0","0","185-246560_IGRA.CEL.gz","2","1","IGR","246560","2","0","3.24","1","1","2","VDXIGRU_246560","1.2","0","3296","3296","3296","3296","Poor"
"GSM177944","VDXIGRU_246821","GSM177944","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246821","Homo sapiens","samplename: VDXIGRU_246821","id: 246821","filename: 193-246821_IGRA.CEL.gz","hospital: IGR","age: 52","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 546","e.rfs: 1","t.os: 3555","e.os: 0","t.dmfs: 3555","e.dmfs: 0","t.tdm: 3555","e.tdm: 0","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 78.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177944/suppl/GSM177944.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","52","1","78.1","0","0","1","0","1","193-246821_IGRA.CEL.gz","2","1","IGR","246821","2","0","3.6","1","2","2","VDXIGRU_246821","3","1","3555","3555","546","3555","Poor"
"GSM177945","VDXIGRU_246919","GSM177945","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_246919","Homo sapiens","samplename: VDXIGRU_246919","id: 246919","filename: 217-246919_IGRA.CEL.gz","hospital: IGR","age: 50","size: 1.5","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 3525","e.rfs: 1","t.os: 5433","e.os: 0","t.dmfs: 5433","e.dmfs: 0","t.tdm: 5433","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 87.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177945/suppl/GSM177945.cel.gz","22283","Reanalyzed by: GSE47561","","50","2","87.6","0","0","1","0","1","217-246919_IGRA.CEL.gz","2","1","IGR","246919","2","0","3.3","1","1","2","VDXIGRU_246919","1.5","0","5433","5433","3525","5433","Poor"
"GSM177946","VDXIGRU_247000","GSM177946","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_247000","Homo sapiens","samplename: VDXIGRU_247000","id: 247000","filename: 40-247000_IGRA.CEL.gz","hospital: IGR","age: 36","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 854","e.rfs: 1","t.os: 5228","e.os: 0","t.dmfs: 5228","e.dmfs: 0","t.tdm: 5228","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 74.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177946/suppl/GSM177946.cel.gz","22283","Reanalyzed by: GSE47561","","36","2","74.8","0","0","1","0","1","40-247000_IGRA.CEL.gz","3","1","IGR","247000","1","0","4.44","1","2","2","VDXIGRU_247000","2.2","0","5228","5228","854","5228","Poor"
"GSM177947","VDXIGRU_247243","GSM177947","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_247243","Homo sapiens","samplename: VDXIGRU_247243","id: 247243","filename: 64-247243_IGRA.CEL.gz","hospital: IGR","age: 45","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1813","e.rfs: 1","t.os: 5316","e.os: 0","t.dmfs: 5316","e.dmfs: 0","t.tdm: 5316","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 80.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177947/suppl/GSM177947.cel.gz","22283","Reanalyzed by: GSE47561","","45","NA","80.4","0","0","1","0","1","64-247243_IGRA.CEL.gz","2","1","IGR","247243","NA","0","3.5","1","2","2","VDXIGRU_247243","2.5","0","5316","5316","1813","5316","Poor"
"GSM177948","VDXIGRU_247401","GSM177948","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_247401","Homo sapiens","samplename: VDXIGRU_247401","id: 247401","filename: 51-247401_IGRA.CEL.gz","hospital: IGR","age: 50","size: 1.7","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 4925","e.rfs: 0","t.os: 4925","e.os: 0","t.dmfs: 4925","e.dmfs: 0","t.tdm: 4925","e.tdm: 0","risksg: 1","NPI: 2.34","risknpi: 1","AOL_os_10y: 92.4","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177948/suppl/GSM177948.cel.gz","22283","Reanalyzed by: GSE47561","","50","1","92.4","0","0","0","0","1","51-247401_IGRA.CEL.gz","1","1","IGR","247401","2","0","2.34","0","1","1","VDXIGRU_247401","1.7","0","4925","4925","4925","4925","Good"
"GSM177949","VDXIGRU_254031","GSM177949","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXIGRU_254031","Homo sapiens","samplename: VDXIGRU_254031","id: 254031","filename: 54-254031_IGRA.CEL.gz","hospital: IGR","age: 39","size: 2.3","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 3853","e.rfs: 1","t.os: 5012","e.os: 0","t.dmfs: 5012","e.dmfs: 0","t.tdm: 5012","e.tdm: 0","risksg: 2","NPI: 4.46","risknpi: 2","AOL_os_10y: 74.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177949/suppl/GSM177949.cel.gz","22283","","","39","NA","74.5","0","0","1","0","1","54-254031_IGRA.CEL.gz","3","1","IGR","254031","NA","0","4.46","1","2","2","VDXIGRU_254031","2.3","0","5012","5012","3853","5012","Poor"
"GSM177950","VDXIGRU_254485","GSM177950","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_254485","Homo sapiens","samplename: VDXIGRU_254485","id: 254485","filename: 179-254485_IGRA.CEL.gz","hospital: IGR","age: 44","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 4642","e.rfs: 0","t.os: 4642","e.os: 0","t.dmfs: 4642","e.dmfs: 0","t.tdm: 4642","e.tdm: 0","risksg: 2","NPI: 2.6","risknpi: 1","AOL_os_10y: 88.4","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177950/suppl/GSM177950.cel.gz","22283","Reanalyzed by: GSE47561","","44","1","88.4","0","0","0","0","1","179-254485_IGRA.CEL.gz","1","1","IGR","254485","1","0","2.6","0","1","2","VDXIGRU_254485","3","0","4642","4642","4642","4642","Good"
"GSM177951","VDXIGRU_255160","GSM177951","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXIGRU_255160","Homo sapiens","samplename: VDXIGRU_255160","id: 255160","filename: 44-255160_IGRA.CEL.gz","hospital: IGR","age: 50","size: 1.3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 3311","e.rfs: 0","t.os: 3311","e.os: 0","t.dmfs: 3311","e.dmfs: 0","t.tdm: 3311","e.tdm: 0","risksg: 1","NPI: 2.26","risknpi: 1","AOL_os_10y: 92.4","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177951/suppl/GSM177951.cel.gz","22283","","","50","1","92.4","0","0","0","0","1","44-255160_IGRA.CEL.gz","1","1","IGR","255160","1","0","2.26","0","1","1","VDXIGRU_255160","1.3","0","3311","3311","3311","3311","Good"
"GSM177952","VDXIGRU_255627","GSM177952","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_255627","Homo sapiens","samplename: VDXIGRU_255627","id: 255627","filename: 222-255627_IGRA.CEL.gz","hospital: IGR","age: 51","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 4863","e.rfs: 0","t.os: 4863","e.os: 0","t.dmfs: 4863","e.dmfs: 0","t.tdm: 4863","e.tdm: 0","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177952/suppl/GSM177952.cel.gz","22283","Reanalyzed by: GSE47561","","51","1","87.2","0","0","0","0","1","222-255627_IGRA.CEL.gz","2","1","IGR","255627","2","0","3.36","1","2","2","VDXIGRU_255627","1.8","0","4863","4863","4863","4863","Poor"
"GSM177953","VDXIGRU_256209","GSM177953","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_256209","Homo sapiens","samplename: VDXIGRU_256209","id: 256209","filename: 227-256209_IGRA.CEL.gz","hospital: IGR","age: 49","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 1780","e.rfs: 1","t.os: 3347","e.os: 1","t.dmfs: 1815","e.dmfs: 1","t.tdm: 1815","e.tdm: 1","risksg: 1","NPI: 2.4","risknpi: 1","AOL_os_10y: 92.8","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177953/suppl/GSM177953.cel.gz","22283","Reanalyzed by: GSE47561","","49","1","92.8","1","1","1","1","1","227-256209_IGRA.CEL.gz","1","1","IGR","256209","1","0","2.4","0","1","1","VDXIGRU_256209","2","1","1815","3347","1780","1815","Poor"
"GSM177954","VDXIGRU_256734","GSM177954","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_256734","Homo sapiens","samplename: VDXIGRU_256734","id: 256734","filename: 220-256734_IGRA.CEL.gz","hospital: IGR","age: 37","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 0","t.rfs: 803","e.rfs: 1","t.os: 1049","e.os: 1","t.dmfs: 803","e.dmfs: 1","t.tdm: 803","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 84.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177954/suppl/GSM177954.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","37","1","84.6","1","1","1","1","0","220-256734_IGRA.CEL.gz","2","1","IGR","256734","1","0","3.4","1","2","2","VDXIGRU_256734","2","0","803","1049","803","803","Poor"
"GSM177955","VDXIGRU_256940","GSM177955","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_256940","Homo sapiens","samplename: VDXIGRU_256940","id: 256940","filename: 55-256940_IGRA.CEL.gz","hospital: IGR","age: 51","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 2105","e.rfs: 0","t.os: 2105","e.os: 0","t.dmfs: 2105","e.dmfs: 0","t.tdm: 2105","e.tdm: 0","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177955/suppl/GSM177955.cel.gz","22283","Reanalyzed by: GSE47561","","51","1","87.2","0","0","0","0","1","55-256940_IGRA.CEL.gz","2","1","IGR","256940","2","0","3.36","1","2","2","VDXIGRU_256940","1.8","0","2105","2105","2105","2105","Poor"
"GSM177956","VDXIGRU_256975","GSM177956","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_256975","Homo sapiens","samplename: VDXIGRU_256975","id: 256975","filename: 183-256975_IGRA.CEL.gz","hospital: IGR","age: 40","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 1","node: 0","grade: 3","er: 0","t.rfs: 530","e.rfs: 1","t.os: 929","e.os: 1","t.dmfs: 530","e.dmfs: 1","t.tdm: 530","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 81.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177956/suppl/GSM177956.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","40","2","81.3","1","1","1","1","0","183-256975_IGRA.CEL.gz","3","1","IGR","256975","1","0","4.4","1","2","2","VDXIGRU_256975","2","0","530","929","530","530","Poor"
"GSM177957","VDXIGRU_271448","GSM177957","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_271448","Homo sapiens","samplename: VDXIGRU_271448","id: 271448","filename: 187-271448_IGRA.CEL.gz","hospital: IGR","age: 44","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 4830","e.rfs: 0","t.os: 4830","e.os: 0","t.dmfs: 4830","e.dmfs: 0","t.tdm: 4830","e.tdm: 0","risksg: 1","NPI: 2.4","risknpi: 1","AOL_os_10y: 94.3","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177957/suppl/GSM177957.cel.gz","22283","Reanalyzed by: GSE47561","","44","1","94.3","0","0","0","0","1","187-271448_IGRA.CEL.gz","1","1","IGR","271448","2","0","2.4","0","1","1","VDXIGRU_271448","2","1","4830","4830","4830","4830","Poor"
"GSM177958","VDXIGRU_271982","GSM177958","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_271982","Homo sapiens","samplename: VDXIGRU_271982","id: 271982","filename: 231-271982_IGRA.CEL.gz","hospital: IGR","age: 49","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 1","t.rfs: 1721","e.rfs: 1","t.os: 2148","e.os: 1","t.dmfs: 1721","e.dmfs: 1","t.tdm: 1721","e.tdm: 1","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 83.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177958/suppl/GSM177958.cel.gz","22283","Reanalyzed by: GSE47561","","49","1","83.2","1","1","1","1","1","231-271982_IGRA.CEL.gz","3","1","IGR","271982","1","0","4.4","1","2","2","VDXIGRU_271982","2","0","1721","2148","1721","1721","Poor"
"GSM177959","VDXIGRU_272219","GSM177959","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_272219","Homo sapiens","samplename: VDXIGRU_272219","id: 272219","filename: 214-272219_IGRA.CEL.gz","hospital: IGR","age: 53","size: 1.5","Surgery_type: 0","Histtype: 7","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 4720","e.rfs: 0","t.os: 4720","e.os: 0","t.dmfs: 4720","e.dmfs: 0","t.tdm: 4720","e.tdm: 0","risksg: 1","NPI: 2.3","risknpi: 1","AOL_os_10y: 90.9","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177959/suppl/GSM177959.cel.gz","22283","Reanalyzed by: GSE47561","","53","1","90.9","0","0","0","0","1","214-272219_IGRA.CEL.gz","1","7","IGR","272219","1","0","2.3","0","1","1","VDXIGRU_272219","1.5","0","4720","4720","4720","4720","Poor"
"GSM177960","VDXIGRU_272823","GSM177960","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_272823","Homo sapiens","samplename: VDXIGRU_272823","id: 272823","filename: 59-272823_IGRA.CEL.gz","hospital: IGR","age: 44","size: 2.9","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 2","er: 1","t.rfs: 1259","e.rfs: 1","t.os: 2453","e.os: 1","t.dmfs: 1259","e.dmfs: 1","t.tdm: 1259","e.tdm: 1","risksg: 2","NPI: 3.58","risknpi: 2","AOL_os_10y: 80.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177960/suppl/GSM177960.cel.gz","22283","Reanalyzed by: GSE47561","","44","1","80.6","1","1","1","1","1","59-272823_IGRA.CEL.gz","2","1","IGR","272823","1","0","3.58","1","2","2","VDXIGRU_272823","2.9","0","1259","2453","1259","1259","Poor"
"GSM177961","VDXIGRU_280328","GSM177961","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_280328","Homo sapiens","samplename: VDXIGRU_280328","id: 280328","filename: 43-280328_IGRA.CEL.gz","hospital: IGR","age: 48","size: 2.3","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 3976","e.rfs: 1","t.os: 4438","e.os: 0","t.dmfs: 3976","e.dmfs: 1","t.tdm: 3976","e.tdm: 1","risksg: 2","NPI: 3.46","risknpi: 2","AOL_os_10y: 79.6","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177961/suppl/GSM177961.cel.gz","22283","Reanalyzed by: GSE47561","","48","NA","79.6","1","0","1","1","1","43-280328_IGRA.CEL.gz","2","1","IGR","280328","NA","0","3.46","1","2","2","VDXIGRU_280328","2.3","1","3976","4438","3976","3976","Good"
"GSM177962","VDXIGRU_280352","GSM177962","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXIGRU_280352","Homo sapiens","samplename: VDXIGRU_280352","id: 280352","filename: 56-280352_IGRA.CEL.gz","hospital: IGR","age: 57","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 3331","e.rfs: 1","t.os: 4469","e.os: 0","t.dmfs: 4050","e.dmfs: 1","t.tdm: 4050","e.tdm: 1","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 75.5","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177962/suppl/GSM177962.cel.gz","22283","","","57","NA","75.5","1","0","1","1","1","56-280352_IGRA.CEL.gz","2","1","IGR","280352","NA","0","3.5","1","2","2","VDXIGRU_280352","2.5","0","4050","4469","3331","4050","Good"
"GSM177963","VDXIGRU_280775","GSM177963","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_280775","Homo sapiens","samplename: VDXIGRU_280775","id: 280775","filename: 66-280775_IGRA.CEL.gz","hospital: IGR","age: 45","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 1","Lymp_infil: 3","node: 0","grade: 3","er: 1","t.rfs: 1740","e.rfs: 0","t.os: 1740","e.os: 0","t.dmfs: 1740","e.dmfs: 0","t.tdm: 1740","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 73.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177963/suppl/GSM177963.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","45","1","73.6","0","0","0","0","1","66-280775_IGRA.CEL.gz","3","1","IGR","280775","3","0","4.6","1","2","2","VDXIGRU_280775","3","1","1740","1740","1740","1740","Poor"
"GSM177964","VDXIGRU_287897","GSM177964","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXIGRU_287897","Homo sapiens","samplename: VDXIGRU_287897","id: 287897","filename: 48-287897_IGRA.CEL.gz","hospital: IGR","age: 44","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 1","er: 1","t.rfs: 3218","e.rfs: 1","t.os: 3608","e.os: 1","t.dmfs: 3608","e.dmfs: 1","t.tdm: 3608","e.tdm: 0","risksg: 1","NPI: 2.4","risknpi: 1","AOL_os_10y: 94.3","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177964/suppl/GSM177964.cel.gz","22283","","","44","1","94.3","1","1","1","0","1","48-287897_IGRA.CEL.gz","1","1","IGR","287897","2","0","2.4","0","1","1","VDXIGRU_287897","2","0","3608","3608","3218","3608","Good"
"GSM177965","VDXIGRU_306818","GSM177965","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_306818","Homo sapiens","samplename: VDXIGRU_306818","id: 306818","filename: 63-306818_IGRA.CEL.gz","hospital: IGR","age: 39","size: 1.5","Surgery_type: 0","Histtype: 1","Angioinv: 2","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 2536","e.rfs: 1","t.os: 3900","e.os: 0","t.dmfs: 3900","e.dmfs: 0","t.tdm: 3900","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 90.3","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177965/suppl/GSM177965.cel.gz","22283","Reanalyzed by: GSE47561","","39","2","90.3","0","0","1","0","1","63-306818_IGRA.CEL.gz","2","1","IGR","306818","2","0","3.3","0","1","2","VDXIGRU_306818","1.5","0","3900","3900","2536","3900","Good"
"GSM177966","VDXIGRU_307251","GSM177966","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_307251","Homo sapiens","samplename: VDXIGRU_307251","id: 307251","filename: 225-307251_IGRA.CEL.gz","hospital: IGR","age: 40","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 0","t.rfs: 1554","e.rfs: 0","t.os: 1554","e.os: 0","t.dmfs: 1554","e.dmfs: 0","t.tdm: 1554","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 67.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177966/suppl/GSM177966.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","40","1","67.6","0","0","0","0","0","225-307251_IGRA.CEL.gz","3","1","IGR","307251","1","0","4.6","1","2","2","VDXIGRU_307251","3","0","1554","1554","1554","1554","Poor"
"GSM177967","VDXIGRU_307327","GSM177967","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_307327","Homo sapiens","samplename: VDXIGRU_307327","id: 307327","filename: 29-307327_IGRA.CEL.gz","hospital: IGR","age: 38","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 2","node: 0","grade: 3","er: 1","t.rfs: 3544","e.rfs: 0","t.os: 3544","e.os: 0","t.dmfs: 3544","e.dmfs: 0","t.tdm: 3544","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 85.5","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177967/suppl/GSM177967.cel.gz","22283","Reanalyzed by: GSE47561","","38","1","85.5","0","0","0","0","1","29-307327_IGRA.CEL.gz","3","1","IGR","307327","2","0","4.4","1","2","2","VDXIGRU_307327","2","0","3544","3544","3544","3544","Good"
"GSM177968","VDXIGRU_307506","GSM177968","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_307506","Homo sapiens","samplename: VDXIGRU_307506","id: 307506","filename: 60-307506_IGRA.CEL.gz","hospital: IGR","age: 45","size: 2.6","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 1","er: 1","t.rfs: 3721","e.rfs: 0","t.os: 3721","e.os: 0","t.dmfs: 3721","e.dmfs: 0","t.tdm: 3721","e.tdm: 0","risksg: 2","NPI: 2.52","risknpi: 1","AOL_os_10y: 88.2","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177968/suppl/GSM177968.cel.gz","22283","Reanalyzed by: GSE47561","","45","1","88.2","0","0","0","0","1","60-307506_IGRA.CEL.gz","1","1","IGR","307506","1","0","2.52","0","1","2","VDXIGRU_307506","2.6","0","3721","3721","3721","3721","Poor"
"GSM177969","VDXIGRU_307829","GSM177969","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_307829","Homo sapiens","samplename: VDXIGRU_307829","id: 307829","filename: 28-307829_IGRA.CEL.gz","hospital: IGR","age: 43","size: 2.6","Surgery_type: 0","Histtype: 1","Angioinv: 3","Lymp_infil: 2","node: 0","grade: 2","er: 1","t.rfs: 3771","e.rfs: 0","t.os: 3771","e.os: 0","t.dmfs: 3771","e.dmfs: 0","t.tdm: 3771","e.tdm: 0","risksg: 2","NPI: 3.52","risknpi: 2","AOL_os_10y: 80.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177969/suppl/GSM177969.cel.gz","22283","Reanalyzed by: GSE47561","","43","3","80.8","0","0","0","0","1","28-307829_IGRA.CEL.gz","2","1","IGR","307829","2","0","3.52","1","2","2","VDXIGRU_307829","2.6","0","3771","3771","3771","3771","Poor"
"GSM177970","VDXIGRU_314827","GSM177970","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXIGRU_314827","Homo sapiens","samplename: VDXIGRU_314827","id: 314827","filename: 57-314827_IGRA.CEL.gz","hospital: IGR","age: 47","size: 1.5","Surgery_type: 0","Histtype: 6","Angioinv: 1","Lymp_infil: 1","node: 0","grade: 3","er: 0","t.rfs: 3293","e.rfs: 0","t.os: 3293","e.os: 0","t.dmfs: 3293","e.dmfs: 0","t.tdm: 3293","e.tdm: 0","risksg: 2","NPI: 4.3","risknpi: 2","AOL_os_10y: 80","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177970/suppl/GSM177970.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","47","1","80","0","0","0","0","0","57-314827_IGRA.CEL.gz","3","6","IGR","314827","1","0","4.3","1","2","2","VDXIGRU_314827","1.5","0","3293","3293","3293","3293","Poor"
"GSM177971","VDXOXFU_37","GSM177971","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_37","Homo sapiens","samplename: VDXOXFU_37","id: 37","filename: 76-37_OXFA.CEL.gz","hospital: JRH","age: 38","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 3093","e.rfs: 1","t.os: 3800","e.os: 0","t.dmfs: 3800","e.dmfs: 0","t.tdm: 3800","e.tdm: 0","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 84.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177971/suppl/GSM177971.cel.gz","22283","Reanalyzed by: GSE47561","","38","1","84.5","0","0","1","0","0","76-37_OXFA.CEL.gz","2","1","JRH","37","NA","0","3.36","1","2","2","VDXOXFU_37","1.8","0","3800","3800","3093","3800","Poor"
"GSM177972","VDXOXFU_57","GSM177972","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_57","Homo sapiens","samplename: VDXOXFU_57","id: 57","filename: 108-57_OXFA.CEL.gz","hospital: JRH","age: 43","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 4396","e.rfs: 1","t.os: 4455","e.os: 0","t.dmfs: 4415","e.dmfs: 1","t.tdm: 4415","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 83.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177972/suppl/GSM177972.cel.gz","22283","Reanalyzed by: GSE47561","","43","NA","83.8","1","0","1","1","0","108-57_OXFA.CEL.gz","2","1","JRH","57","NA","0","3.4","1","2","2","VDXOXFU_57","2","1","4415","4455","4396","4415","Poor"
"GSM177973","VDXOXFU_104","GSM177973","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_104","Homo sapiens","samplename: VDXOXFU_104","id: 104","filename: 74-104_OXFA.CEL.gz","hospital: JRH","age: 60","size: 3.1","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 649","e.rfs: 1","t.os: 1029","e.os: 1","t.dmfs: 649","e.dmfs: 1","t.tdm: 649","e.tdm: 1","risksg: 2","NPI: 4.62","risknpi: 2","AOL_os_10y: 59.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177973/suppl/GSM177973.cel.gz","22283","Reanalyzed by: GSE47561","","60","NA","59.9","1","1","1","1","1","74-104_OXFA.CEL.gz","3","3","JRH","104","NA","0","4.62","1","2","2","VDXOXFU_104","3.1","0","649","1029","649","649","Poor"
"GSM177974","VDXOXFU_157","GSM177974","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_157","Homo sapiens","samplename: VDXOXFU_157","id: 157","filename: 86-157_OXFA.CEL.gz","hospital: JRH","age: 42","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 4945","e.rfs: 1","t.os: 4952","e.os: 0","t.dmfs: 4952","e.dmfs: 0","t.tdm: 4952","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 89.8","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177974/suppl/GSM177974.cel.gz","22283","Reanalyzed by: GSE47561","","42","NA","89.8","0","0","1","0","1","86-157_OXFA.CEL.gz","2","1","JRH","157","NA","0","3.4","0","2","2","VDXOXFU_157","2","0","4952","4952","4945","4952","Poor"
"GSM177975","VDXOXFU_194","GSM177975","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_194","Homo sapiens","samplename: VDXOXFU_194","id: 194","filename: 85-194_OXFA.CEL.gz","hospital: JRH","age: 46","size: 2.1","Surgery_type: 1","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 1693","e.rfs: 1","t.os: 2985","e.os: 1","t.dmfs: 1693","e.dmfs: 1","t.tdm: 1693","e.tdm: 1","risksg: 2","NPI: 4.42","risknpi: 2","AOL_os_10y: 66.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177975/suppl/GSM177975.cel.gz","22283","Reanalyzed by: GSE47561","","46","NA","66.6","1","1","1","1","0","85-194_OXFA.CEL.gz","3","3","JRH","194","NA","0","4.42","1","2","2","VDXOXFU_194","2.1","1","1693","2985","1693","1693","Poor"
"GSM177976","VDXOXFU_220","GSM177976","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_220","Homo sapiens","samplename: VDXOXFU_220","id: 220","filename: 87-220_OXFA.CEL.gz","hospital: JRH","age: 47","size: 1","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 3725","e.rfs: 1","t.os: 4603","e.os: 0","t.dmfs: 4603","e.dmfs: 0","t.tdm: 4603","e.tdm: 0","risksg: 2","NPI: 3.2","risknpi: 1","AOL_os_10y: 91.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177976/suppl/GSM177976.cel.gz","22283","Reanalyzed by: GSE47561","","47","NA","91.6","0","0","1","0","0","87-220_OXFA.CEL.gz","2","1","JRH","220","NA","0","3.2","1","1","2","VDXOXFU_220","1","0","4603","4603","3725","4603","Poor"
"GSM177977","VDXOXFU_245","GSM177977","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_245","Homo sapiens","samplename: VDXOXFU_245","id: 245","filename: 102-245_OXFA.CEL.gz","hospital: JRH","age: 54","size: 1","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4857","e.rfs: 0","t.os: 4857","e.os: 0","t.dmfs: 4857","e.dmfs: 0","t.tdm: 4857","e.tdm: 0","risksg: 2","NPI: 4.2","risknpi: 2","AOL_os_10y: 85.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177977/suppl/GSM177977.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","85.7","0","0","0","0","0","102-245_OXFA.CEL.gz","3","1","JRH","245","NA","0","4.2","1","2","2","VDXOXFU_245","1","0","4857","4857","4857","4857","Poor"
"GSM177978","VDXOXFU_316","GSM177978","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_316","Homo sapiens","samplename: VDXOXFU_316","id: 316","filename: 105-316_OXFA.CEL.gz","hospital: JRH","age: 47","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4681","e.rfs: 0","t.os: 4681","e.os: 0","t.dmfs: 4681","e.dmfs: 0","t.tdm: 4681","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 66.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177978/suppl/GSM177978.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","47","NA","66.4","0","0","0","0","0","105-316_OXFA.CEL.gz","3","1","JRH","316","NA","0","4.44","1","2","2","VDXOXFU_316","2.2","0","4681","4681","4681","4681","Poor"
"GSM177979","VDXOXFU_320","GSM177979","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_320","Homo sapiens","samplename: VDXOXFU_320","id: 320","filename: 96-320_OXFA.CEL.gz","hospital: JRH","age: 39","size: 5","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 2561","e.rfs: 1","t.os: 2965","e.os: 1","t.dmfs: 2965","e.dmfs: 1","t.tdm: 2965","e.tdm: 0","risksg: 2","NPI: 5","risknpi: 2","AOL_os_10y: 63.7","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177979/suppl/GSM177979.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","39","NA","63.7","1","1","1","0","0","96-320_OXFA.CEL.gz","3","1","JRH","320","NA","0","5","1","2","2","VDXOXFU_320","5","1","2965","2965","2561","2965","Good"
"GSM177980","VDXOXFU_360","GSM177980","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_360","Homo sapiens","samplename: VDXOXFU_360","id: 360","filename: 98-360_OXFA.CEL.gz","hospital: JRH","age: 32","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4596","e.rfs: 0","t.os: 4596","e.os: 0","t.dmfs: 4596","e.dmfs: 0","t.tdm: 4596","e.tdm: 0","risksg: 2","NPI: 4.6","risknpi: 2","AOL_os_10y: 68.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177980/suppl/GSM177980.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","32","NA","68.2","0","0","0","0","0","98-360_OXFA.CEL.gz","3","1","JRH","360","NA","0","4.6","1","2","2","VDXOXFU_360","3","0","4596","4596","4596","4596","Poor"
"GSM177981","VDXOXFU_366","GSM177981","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_366","Homo sapiens","samplename: VDXOXFU_366","id: 366","filename: 75-366_OXFA.CEL.gz","hospital: JRH","age: 57","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 1038","e.rfs: 1","t.os: 1205","e.os: 1","t.dmfs: 1112","e.dmfs: 1","t.tdm: 1112","e.tdm: 1","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 62.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177981/suppl/GSM177981.cel.gz","22283","Reanalyzed by: GSE47561","","57","NA","62.7","1","1","1","1","0","75-366_OXFA.CEL.gz","3","1","JRH","366","NA","0","4.5","1","2","2","VDXOXFU_366","2.5","1","1112","1205","1038","1112","Poor"
"GSM177982","VDXOXFU_513","GSM177982","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_513","Homo sapiens","samplename: VDXOXFU_513","id: 513","filename: 79-513_OXFA.CEL.gz","hospital: JRH","age: 47","size: 3.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 1141","e.rfs: 1","t.os: 1918","e.os: 1","t.dmfs: 1918","e.dmfs: 1","t.tdm: 1918","e.tdm: 0","risksg: 2","NPI: 3.76","risknpi: 2","AOL_os_10y: 64.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177982/suppl/GSM177982.cel.gz","22283","Reanalyzed by: GSE47561","","47","NA","64.5","1","1","1","0","0","79-513_OXFA.CEL.gz","2","1","JRH","513","NA","0","3.76","1","2","2","VDXOXFU_513","3.8","0","1918","1918","1141","1918","Poor"
"GSM177983","VDXOXFU_530","GSM177983","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_530","Homo sapiens","samplename: VDXOXFU_530","id: 530","filename: 89-530_OXFA.CEL.gz","hospital: JRH","age: 54","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 996","e.rfs: 1","t.os: 2111","e.os: 1","t.dmfs: 1731","e.dmfs: 1","t.tdm: 1731","e.tdm: 1","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 85.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177983/suppl/GSM177983.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","85.7","1","1","1","1","1","89-530_OXFA.CEL.gz","2","1","JRH","530","NA","0","3.36","1","2","2","VDXOXFU_530","1.8","0","1731","2111","996","1731","Poor"
"GSM177984","VDXOXFU_544","GSM177984","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_544","Homo sapiens","samplename: VDXOXFU_544","id: 544","filename: 95-544_OXFA.CEL.gz","hospital: JRH","age: 54","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 4327","e.rfs: 0","t.os: 4327","e.os: 0","t.dmfs: 4327","e.dmfs: 0","t.tdm: 4327","e.tdm: 0","risksg: 1","NPI: 2.36","risknpi: 1","AOL_os_10y: 90.3","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177984/suppl/GSM177984.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","90.3","0","0","0","0","1","95-544_OXFA.CEL.gz","1","1","JRH","544","NA","0","2.36","0","1","1","VDXOXFU_544","1.8","0","4327","4327","4327","4327","Poor"
"GSM177985","VDXOXFU_547","GSM177985","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_547","Homo sapiens","samplename: VDXOXFU_547","id: 547","filename: 80-547_OXFA.CEL.gz","hospital: JRH","age: 45","size: 4","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4352","e.rfs: 0","t.os: 4352","e.os: 0","t.dmfs: 4352","e.dmfs: 0","t.tdm: 4352","e.tdm: 0","risksg: 2","NPI: 4.8","risknpi: 2","AOL_os_10y: 62.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177985/suppl/GSM177985.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","45","NA","62.9","0","0","0","0","0","80-547_OXFA.CEL.gz","3","1","JRH","547","NA","0","4.8","1","2","2","VDXOXFU_547","4","0","4352","4352","4352","4352","Poor"
"GSM177986","VDXOXFU_662","GSM177986","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_662","Homo sapiens","samplename: VDXOXFU_662","id: 662","filename: 100-662_OXFA.CEL.gz","hospital: JRH","age: 43","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 2083","e.rfs: 1","t.os: 4181","e.os: 0","t.dmfs: 4181","e.dmfs: 0","t.tdm: 4181","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 74","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177986/suppl/GSM177986.cel.gz","22283","Reanalyzed by: GSE47561","","43","1","74","0","0","1","0","1","100-662_OXFA.CEL.gz","3","1","JRH","662","NA","0","4.44","1","2","2","VDXOXFU_662","2.2","0","4181","4181","2083","4181","Poor"
"GSM177987","VDXOXFU_869","GSM177987","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXOXFU_869","Homo sapiens","samplename: VDXOXFU_869","id: 869","filename: 83-869_OXFA.CEL.gz","hospital: JRH","age: 48","size: 1","Surgery_type: 0","Histtype: 7","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 3188","e.rfs: 0","t.os: 3188","e.os: 0","t.dmfs: 3188","e.dmfs: 0","t.tdm: 3188","e.tdm: 0","risksg: 1","NPI: 2.2","risknpi: 1","AOL_os_10y: 95.1","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177987/suppl/GSM177987.cel.gz","22283","","","48","NA","95.1","0","0","0","0","1","83-869_OXFA.CEL.gz","1","7","JRH","869","NA","0","2.2","0","1","1","VDXOXFU_869","1","0","3188","3188","3188","3188","Good"
"GSM177988","VDXOXFU_1006","GSM177988","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1006","Homo sapiens","samplename: VDXOXFU_1006","id: 1006","filename: 99-1006_OXFA.CEL.gz","hospital: JRH","age: 43","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 2672","e.rfs: 0","t.os: 2672","e.os: 0","t.dmfs: 2672","e.dmfs: 0","t.tdm: 2672","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 84.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177988/suppl/GSM177988.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","43","NA","84.8","0","0","0","0","1","99-1006_OXFA.CEL.gz","3","1","JRH","1006","NA","0","4.4","1","2","2","VDXOXFU_1006","2","0","2672","2672","2672","2672","Good"
"GSM177989","VDXOXFU_1065","GSM177989","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1065","Homo sapiens","samplename: VDXOXFU_1065","id: 1065","filename: 103-1065_OXFA.CEL.gz","hospital: JRH","age: 43","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 730","e.rfs: 1","t.os: 794","e.os: 1","t.dmfs: 730","e.dmfs: 1","t.tdm: 730","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 89.6","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177989/suppl/GSM177989.cel.gz","22283","Reanalyzed by: GSE47561","","43","NA","89.6","1","1","1","1","1","103-1065_OXFA.CEL.gz","2","1","JRH","1065","NA","0","3.4","0","2","2","VDXOXFU_1065","2","0","730","794","730","730","Poor"
"GSM177990","VDXOXFU_1183","GSM177990","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1183","Homo sapiens","samplename: VDXOXFU_1183","id: 1183","filename: 97-1183_OXFA.CEL.gz","hospital: JRH","age: 50","size: 0.8","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 1591","e.rfs: 0","t.os: 1591","e.os: 0","t.dmfs: 1591","e.dmfs: 0","t.tdm: 1591","e.tdm: 0","risksg: 1","NPI: 2.16","risknpi: 1","AOL_os_10y: 94.3","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177990/suppl/GSM177990.cel.gz","22283","Reanalyzed by: GSE47561","","50","1","94.3","0","0","0","0","1","97-1183_OXFA.CEL.gz","1","1","JRH","1183","NA","0","2.16","0","1","1","VDXOXFU_1183","0.8","0","1591","1591","1591","1591","Poor"
"GSM177991","VDXOXFU_1210","GSM177991","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1210","Homo sapiens","samplename: VDXOXFU_1210","id: 1210","filename: 94-1210_OXFA.CEL.gz","hospital: JRH","age: 43","size: 0.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 1920","e.rfs: 0","t.os: 1920","e.os: 0","t.dmfs: 1920","e.dmfs: 0","t.tdm: 1920","e.tdm: 0","risksg: 1","NPI: 2.16","risknpi: 1","AOL_os_10y: 96.5","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177991/suppl/GSM177991.cel.gz","22283","Reanalyzed by: GSE47561","","43","NA","96.5","0","0","0","0","1","94-1210_OXFA.CEL.gz","1","1","JRH","1210","NA","0","2.16","0","1","1","VDXOXFU_1210","0.8","0","1920","1920","1920","1920","Good"
"GSM177992","VDXOXFU_1328","GSM177992","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1328","Homo sapiens","samplename: VDXOXFU_1328","id: 1328","filename: 84-1328_OXFA.CEL.gz","hospital: JRH","age: 49","size: 1.3","Surgery_type: 0","Histtype: 2","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 2647","e.rfs: 0","t.os: 2647","e.os: 0","t.dmfs: 2647","e.dmfs: 0","t.tdm: 2647","e.tdm: 0","risksg: 2","NPI: 3.26","risknpi: 1","AOL_os_10y: 88","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177992/suppl/GSM177992.cel.gz","22283","Reanalyzed by: GSE47561","","49","NA","88","0","0","0","0","1","84-1328_OXFA.CEL.gz","2","2","JRH","1328","NA","0","3.26","0","1","2","VDXOXFU_1328","1.3","0","2647","2647","2647","2647","Poor"
"GSM177993","VDXOXFU_1373","GSM177993","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXOXFU_1373","Homo sapiens","samplename: VDXOXFU_1373","id: 1373","filename: 91-1373_OXFA.CEL.gz","hospital: JRH","age: 38","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 3","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 269","e.rfs: 1","t.os: 413","e.os: 1","t.dmfs: 269","e.dmfs: 1","t.tdm: 269","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 84.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177993/suppl/GSM177993.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","38","3","84.5","1","1","1","1","0","91-1373_OXFA.CEL.gz","2","1","JRH","1373","NA","0","3.4","1","2","2","VDXOXFU_1373","2","0","269","413","269","269","Poor"
"GSM177994","VDXOXFU_1415","GSM177994","Public on Jun 11 2007","Mar 28 2007","Sep 23 2011","RNA","1","VDXOXFU_1415","Homo sapiens","samplename: VDXOXFU_1415","id: 1415","filename: 82-1415_OXFA.CEL.gz","hospital: JRH","age: 47","size: 0.9","Surgery_type: 0","Histtype: 2","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 1290","e.rfs: 0","t.os: 1290","e.os: 0","t.dmfs: 1290","e.dmfs: 0","t.tdm: 1290","e.tdm: 0","risksg: 2","NPI: 3.18","risknpi: 1","AOL_os_10y: 91.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177994/suppl/GSM177994.cel.gz","22283","Reanalyzed by: GSE31519","","47","NA","91.6","0","0","0","0","0","82-1415_OXFA.CEL.gz","2","2","JRH","1415","NA","0","3.18","1","1","2","VDXOXFU_1415","0.9","0","1290","1290","1290","1290","Poor"
"GSM177995","VDXKIU_121","GSM177995","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_121","Homo sapiens","samplename: VDXKIU_121","id: 121","filename: 245_-121_KIA.CEL.gz","hospital: KAR","age: 54","size: 1","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 4568","e.rfs: 0","t.os: 4568","e.os: 0","t.dmfs: 4568","e.dmfs: 0","t.tdm: 4568","e.tdm: 0","risksg: 2","NPI: 3.2","risknpi: 1","AOL_os_10y: 90.3","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177995/suppl/GSM177995.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","90.3","0","0","0","0","1","245_-121_KIA.CEL.gz","2","1","KAR","121","NA","0","3.2","0","1","2","VDXKIU_121","1","1","4568","4568","4568","4568","Poor"
"GSM177996","VDXKIU_205","GSM177996","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_205","Homo sapiens","samplename: VDXKIU_205","id: 205","filename: 238-205_KIA.CEL.gz","hospital: KAR","age: 52","size: 1.9","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 4537","e.rfs: 0","t.os: 4537","e.os: 0","t.dmfs: 4537","e.dmfs: 0","t.tdm: 4537","e.tdm: 0","risksg: 1","NPI: 2.38","risknpi: 1","AOL_os_10y: 91.5","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177996/suppl/GSM177996.cel.gz","22283","Reanalyzed by: GSE47561","","52","NA","91.5","0","0","0","0","1","238-205_KIA.CEL.gz","1","1","KAR","205","NA","0","2.38","0","1","1","VDXKIU_205","1.9","0","4537","4537","4537","4537","Good"
"GSM177997","VDXKIU_386","GSM177997","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_386","Homo sapiens","samplename: VDXKIU_386","id: 386","filename: 147-386_KIA.CEL.gz","hospital: KAR","age: 51","size: 1.4","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5035","e.rfs: 0","t.os: 5035","e.os: 0","t.dmfs: 5035","e.dmfs: 0","t.tdm: 5035","e.tdm: 0","risksg: 2","NPI: 3.28","risknpi: 1","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177997/suppl/GSM177997.cel.gz","22283","Reanalyzed by: GSE47561","","51","NA","87.2","0","0","0","0","1","147-386_KIA.CEL.gz","2","1","KAR","386","NA","0","3.28","1","1","2","VDXKIU_386","1.4","0","5035","5035","5035","5035","Poor"
"GSM177998","VDXKIU_440","GSM177998","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_440","Homo sapiens","samplename: VDXKIU_440","id: 440","filename: 201-440_KIA.CEL.gz","hospital: KAR","age: 50","size: 0.9","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1465","e.rfs: 1","t.os: 3207","e.os: 1","t.dmfs: 2604","e.dmfs: 1","t.tdm: 2604","e.tdm: 1","risksg: 2","NPI: 3.18","risknpi: 1","AOL_os_10y: 92.4","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177998/suppl/GSM177998.cel.gz","22283","Reanalyzed by: GSE47561","","50","NA","92.4","1","1","1","1","1","201-440_KIA.CEL.gz","2","1","KAR","440","NA","0","3.18","0","1","2","VDXKIU_440","0.9","0","2604","3207","1465","2604","Poor"
"GSM177999","VDXKIU_1000","GSM177999","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_1000","Homo sapiens","samplename: VDXKIU_1000","id: 1000","filename: 186-1000_KIA.CEL.gz","hospital: KAR","age: 43","size: 4","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 394","e.rfs: 1","t.os: 491","e.os: 1","t.dmfs: 394","e.dmfs: 1","t.tdm: 394","e.tdm: 1","risksg: 2","NPI: 3.8","risknpi: 2","AOL_os_10y: 65.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM177nnn/GSM177999/suppl/GSM177999.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","43","NA","65.3","1","1","1","1","0","186-1000_KIA.CEL.gz","2","1","KAR","1000","NA","0","3.8","1","2","2","VDXKIU_1000","4","1","394","491","394","394","Poor"
"GSM178000","VDXKIU_1246","GSM178000","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_1246","Homo sapiens","samplename: VDXKIU_1246","id: 1246","filename: 212-1246_KIA.CEL.gz","hospital: KAR","age: 24","size: 0.9","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 3512","e.rfs: 1","t.os: 8251","e.os: 0","t.dmfs: 6777","e.dmfs: 1","t.tdm: 6777","e.tdm: 0","risksg: 2","NPI: 3.18","risknpi: 1","AOL_os_10y: 95.4","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178000/suppl/GSM178000.cel.gz","22283","Reanalyzed by: GSE47561","","24","NA","95.4","1","0","1","0","1","212-1246_KIA.CEL.gz","2","1","KAR","1246","NA","0","3.18","0","1","2","VDXKIU_1246","0.9","1","6777","8251","3512","6777","Poor"
"GSM178001","VDXKIU_15E2","GSM178001","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15E2","Homo sapiens","samplename: VDXKIU_15E2","id: 1500","filename: 145-15E2_KIA.CEL.gz","hospital: KAR","age: 40","size: 1.4","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 2549","e.rfs: 0","t.os: 2549","e.os: 0","t.dmfs: 2549","e.dmfs: 0","t.tdm: 2549","e.tdm: 0","risksg: 2","NPI: 4.28","risknpi: 2","AOL_os_10y: 85.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178001/suppl/GSM178001.cel.gz","22283","Reanalyzed by: GSE47561","","40","NA","85.2","0","0","0","0","1","145-15E2_KIA.CEL.gz","3","1","KAR","1500","NA","0","4.28","1","2","2","VDXKIU_15E2","1.4","0","2549","2549","2549","2549","Poor"
"GSM178002","VDXKIU_1608","GSM178002","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_1608","Homo sapiens","samplename: VDXKIU_1608","id: 1608","filename: 134-1608_KIA.CEL.gz","hospital: KAR","age: 56","size: 1","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 4085","e.rfs: 0","t.os: 4085","e.os: 0","t.dmfs: 4085","e.dmfs: 0","t.tdm: 4085","e.tdm: 0","risksg: 2","NPI: 3.2","risknpi: 1","AOL_os_10y: 89","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178002/suppl/GSM178002.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","89","0","0","0","0","1","134-1608_KIA.CEL.gz","2","1","KAR","1608","NA","0","3.2","0","1","2","VDXKIU_1608","1","1","4085","4085","4085","4085","Poor"
"GSM178003","VDXKIU_1708","GSM178003","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_1708","Homo sapiens","samplename: VDXKIU_1708","id: 1708","filename: 196-1708_KIA.CEL.gz","hospital: KAR","age: 43","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 2892","e.rfs: 1","t.os: 2892","e.os: 1","t.dmfs: 2892","e.dmfs: 1","t.tdm: 2892","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 80.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178003/suppl/GSM178003.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","43","NA","80.8","1","1","1","0","0","196-1708_KIA.CEL.gz","3","1","KAR","1708","NA","0","4.4","1","2","2","VDXKIU_1708","2","0","2892","2892","2892","2892","Good"
"GSM178004","VDXKIU_2481","GSM178004","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_2481","Homo sapiens","samplename: VDXKIU_2481","id: 2481","filename: 138-2481_KIA.CEL.gz","hospital: KAR","age: 50","size: 1.1","Surgery_type: 1","Histtype: 2","Angioinv: NA","Lymp_infil: NA","node: 0","grade: NA","er: 1","t.rfs: 2441","e.rfs: 1","t.os: 5236","e.os: 0","t.dmfs: 5236","e.dmfs: 0","t.tdm: 5236","e.tdm: 0","risksg: NA","NPI: NA","risknpi: NA","AOL_os_10y: 87.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178004/suppl/GSM178004.cel.gz","22283","Reanalyzed by: GSE47561","","50","NA","87.6","0","0","1","0","1","138-2481_KIA.CEL.gz","NA","2","KAR","2481","NA","0","NA","1","NA","NA","VDXKIU_2481","1.1","1","5236","5236","2441","5236","Poor"
"GSM178005","VDXKIU_2656","GSM178005","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_2656","Homo sapiens","samplename: VDXKIU_2656","id: 2656","filename: 126-2656_KIA.CEL.gz","hospital: KAR","age: 54","size: 1","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 5406","e.rfs: 0","t.os: 5406","e.os: 0","t.dmfs: 5406","e.dmfs: 0","t.tdm: 5406","e.tdm: 0","risksg: 1","NPI: 2.2","risknpi: 1","AOL_os_10y: 92.2","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178005/suppl/GSM178005.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","92.2","0","0","0","0","1","126-2656_KIA.CEL.gz","1","1","KAR","2656","NA","0","2.2","0","1","1","VDXKIU_2656","1","0","5406","5406","5406","5406","Poor"
"GSM178006","VDXKIU_2743","GSM178006","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_2743","Homo sapiens","samplename: VDXKIU_2743","id: 2743","filename: 113-2743_KIA.CEL.gz","hospital: KAR","age: 45","size: 2.2","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4279","e.rfs: 0","t.os: 4279","e.os: 0","t.dmfs: 4279","e.dmfs: 0","t.tdm: 4279","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 66.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178006/suppl/GSM178006.cel.gz","22283","Reanalyzed by: GSE47561","","45","NA","66.9","0","0","0","0","0","113-2743_KIA.CEL.gz","3","1","KAR","2743","NA","0","4.44","1","2","2","VDXKIU_2743","2.2","1","4279","4279","4279","4279","Poor"
"GSM178007","VDXKIU_2889","GSM178007","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_2889","Homo sapiens","samplename: VDXKIU_2889","id: 2889","filename: 118-2889_KIA.CEL.gz","hospital: KAR","age: 43","size: 1.2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1520","e.rfs: 1","t.os: 5359","e.os: 0","t.dmfs: 5359","e.dmfs: 0","t.tdm: 5359","e.tdm: 0","risksg: 2","NPI: 3.24","risknpi: 1","AOL_os_10y: 89.6","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178007/suppl/GSM178007.cel.gz","22283","Reanalyzed by: GSE47561","","43","NA","89.6","0","0","1","0","1","118-2889_KIA.CEL.gz","2","1","KAR","2889","NA","0","3.24","0","1","2","VDXKIU_2889","1.2","0","5359","5359","1520","5359","Good"
"GSM178008","VDXKIU_2946","GSM178008","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_2946","Homo sapiens","samplename: VDXKIU_2946","id: 2946","filename: 142_-2946_KIA.CEL.gz","hospital: KAR","age: 49","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 3964","e.rfs: 0","t.os: 3964","e.os: 0","t.dmfs: 3964","e.dmfs: 0","t.tdm: 3964","e.tdm: 0","risksg: 1","NPI: 2.4","risknpi: 1","AOL_os_10y: 92.8","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178008/suppl/GSM178008.cel.gz","22283","Reanalyzed by: GSE47561","","49","NA","92.8","0","0","0","0","1","142_-2946_KIA.CEL.gz","1","1","KAR","2946","NA","0","2.4","0","1","1","VDXKIU_2946","2","0","3964","3964","3964","3964","Poor"
"GSM178009","VDXKIU_3367","GSM178009","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_3367","Homo sapiens","samplename: VDXKIU_3367","id: 3367","filename: 190-3367_KIA.CEL.gz","hospital: KAR","age: 53","size: 3.8","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 277","e.rfs: 1","t.os: 642","e.os: 1","t.dmfs: 289","e.dmfs: 1","t.tdm: 289","e.tdm: 1","risksg: 2","NPI: 4.76","risknpi: 2","AOL_os_10y: 60.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178009/suppl/GSM178009.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","53","NA","60.8","1","1","1","1","0","190-3367_KIA.CEL.gz","3","1","KAR","3367","NA","0","4.76","1","2","2","VDXKIU_3367","3.8","1","289","642","277","289","Poor"
"GSM178010","VDXKIU_15E6","GSM178010","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15E6","Homo sapiens","samplename: VDXKIU_15E6","id: 15000000","filename: 131-15E6_KIA.CEL.gz","hospital: KAR","age: 39","size: 1.1","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 6298","e.rfs: 0","t.os: 6298","e.os: 0","t.dmfs: 6298","e.dmfs: 0","t.tdm: 6298","e.tdm: 0","risksg: 2","NPI: 4.22","risknpi: 2","AOL_os_10y: 81.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178010/suppl/GSM178010.cel.gz","22283","Reanalyzed by: GSE47561","","39","NA","81.4","0","0","0","0","0","131-15E6_KIA.CEL.gz","3","1","KAR","15000000","NA","0","4.22","1","2","2","VDXKIU_15E6","1.1","1","6298","6298","6298","6298","Poor"
"GSM178011","VDXKIU_15E7","GSM178011","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15E7","Homo sapiens","samplename: VDXKIU_15E7","id: 150000000","filename: 215-15E7_KIA.CEL.gz","hospital: KAR","age: 38","size: 2.2","Surgery_type: 0","Histtype: 6","Angioinv: NA","Lymp_infil: NA","node: 0","grade: NA","er: 1","t.rfs: 4972","e.rfs: 1","t.os: 6399","e.os: 0","t.dmfs: 6399","e.dmfs: 0","t.tdm: 6399","e.tdm: 0","risksg: 2","NPI: NA","risknpi: NA","AOL_os_10y: 78.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178011/suppl/GSM178011.cel.gz","22283","Reanalyzed by: GSE47561","","38","NA","78.6","0","0","1","0","1","215-15E7_KIA.CEL.gz","NA","6","KAR","150000000","NA","0","NA","1","NA","2","VDXKIU_15E7","2.2","0","6399","6399","4972","6399","Poor"
"GSM178012","VDXKIU_15E8","GSM178012","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15E8","Homo sapiens","samplename: VDXKIU_15E8","id: 1500000000","filename: 243_-15E8_KIA.CEL.gz","hospital: KAR","age: 38","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5683","e.rfs: 0","t.os: 5683","e.os: 0","t.dmfs: 5683","e.dmfs: 0","t.tdm: 5683","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 85.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178012/suppl/GSM178012.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","38","NA","85.5","0","0","0","0","1","243_-15E8_KIA.CEL.gz","3","1","KAR","1500000000","NA","0","4.4","1","2","2","VDXKIU_15E8","2","0","5683","5683","5683","5683","Poor"
"GSM178013","VDXKIU_101B88","GSM178013","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_101B88","Homo sapiens","samplename: VDXKIU_101B88","id: 101B88","filename: 229-101B88_KIA.CEL.gz","hospital: KAR","age: 40","size: 1.2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 6240","e.rfs: 0","t.os: 6240","e.os: 0","t.dmfs: 6240","e.dmfs: 0","t.tdm: 6240","e.tdm: 0","risksg: 2","NPI: 4.24","risknpi: 2","AOL_os_10y: 81.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178013/suppl/GSM178013.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","40","NA","81.3","0","0","0","0","0","229-101B88_KIA.CEL.gz","3","1","KAR","101B88","NA","0","4.24","1","2","2","VDXKIU_101B88","1.2","0","6240","6240","6240","6240","Poor"
"GSM178014","VDXKIU_125B43","GSM178014","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_125B43","Homo sapiens","samplename: VDXKIU_125B43","id: 125B43","filename: 124-125B43_KIA.CEL.gz","hospital: KAR","age: 38","size: 1.5","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 6161","e.rfs: 0","t.os: 6161","e.os: 0","t.dmfs: 6161","e.dmfs: 0","t.tdm: 6161","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 90.4","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178014/suppl/GSM178014.cel.gz","22283","Reanalyzed by: GSE47561","","38","NA","90.4","0","0","0","0","1","124-125B43_KIA.CEL.gz","2","3","KAR","125B43","NA","0","3.3","0","1","2","VDXKIU_125B43","1.5","0","6161","6161","6161","6161","Poor"
"GSM178015","VDXKIU_136B04","GSM178015","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_136B04","Homo sapiens","samplename: VDXKIU_136B04","id: 136B04","filename: 144-136B04_KIA.CEL.gz","hospital: KAR","age: 54","size: 1.7","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 892","e.rfs: 1","t.os: 6132","e.os: 0","t.dmfs: 6132","e.dmfs: 0","t.tdm: 6132","e.tdm: 0","risksg: 2","NPI: 3.34","risknpi: 2","AOL_os_10y: 85.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178015/suppl/GSM178015.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","85.7","0","0","1","0","1","144-136B04_KIA.CEL.gz","2","1","KAR","136B04","NA","0","3.34","1","2","2","VDXKIU_136B04","1.7","0","6132","6132","892","6132","Poor"
"GSM178016","VDXKIU_144B49","GSM178016","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_144B49","Homo sapiens","samplename: VDXKIU_144B49","id: 144B49","filename: 146-144B49_KIA.CEL.gz","hospital: KAR","age: 40","size: 2.1","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 4212","e.rfs: 1","t.os: 5337","e.os: 1","t.dmfs: 4212","e.dmfs: 1","t.tdm: 4212","e.tdm: 1","risksg: 2","NPI: 3.42","risknpi: 2","AOL_os_10y: 81.4","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178016/suppl/GSM178016.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","40","NA","81.4","1","1","1","1","1","146-144B49_KIA.CEL.gz","2","1","KAR","144B49","NA","0","3.42","1","2","2","VDXKIU_144B49","2.1","1","4212","5337","4212","4212","Good"
"GSM178017","VDXKIU_15C5","GSM178017","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15C5","Homo sapiens","samplename: VDXKIU_15C5","id: 15C5","filename: 120-15C5_KIA.CEL.gz","hospital: KAR","age: 56","size: 1","Surgery_type: 1","Histtype: NA","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4980","e.rfs: 0","t.os: 4980","e.os: 0","t.dmfs: 4980","e.dmfs: 0","t.tdm: 4980","e.tdm: 0","risksg: 2","NPI: 4.2","risknpi: 2","AOL_os_10y: 84.4","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178017/suppl/GSM178017.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","84.4","0","0","0","0","0","120-15C5_KIA.CEL.gz","3","NA","KAR","15C5","NA","0","4.2","1","2","2","VDXKIU_15C5","1","1","4980","4980","4980","4980","Good"
"GSM178018","VDXKIU_15D6","GSM178018","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15D6","Homo sapiens","samplename: VDXKIU_15D6","id: 15D6","filename: 129-15D6_KIA.CEL.gz","hospital: KAR","age: 45","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1703","e.rfs: 1","t.os: 1703","e.os: 1","t.dmfs: 1703","e.dmfs: 1","t.tdm: 1703","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 89.2","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178018/suppl/GSM178018.cel.gz","22283","Reanalyzed by: GSE47561","","45","NA","89.2","1","1","1","0","1","129-15D6_KIA.CEL.gz","2","1","KAR","15D6","NA","0","3.4","0","2","2","VDXKIU_15D6","2","0","1703","1703","1703","1703","Poor"
"GSM178019","VDXKIU_15D7","GSM178019","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15D7","Homo sapiens","samplename: VDXKIU_15D7","id: 15D7","filename: 112-15D7_KIA.CEL.gz","hospital: KAR","age: 46","size: 2","Surgery_type: 0","Histtype: 2","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5014","e.rfs: 0","t.os: 5014","e.os: 0","t.dmfs: 5014","e.dmfs: 0","t.tdm: 5014","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 88.9","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178019/suppl/GSM178019.cel.gz","22283","Reanalyzed by: GSE47561","","46","NA","88.9","0","0","0","0","1","112-15D7_KIA.CEL.gz","2","2","KAR","15D7","NA","0","3.4","0","2","2","VDXKIU_15D7","2","0","5014","5014","5014","5014","Poor"
"GSM178020","VDXKIU_15D9","GSM178020","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15D9","Homo sapiens","samplename: VDXKIU_15D9","id: 15D9","filename: 136-15D9_KIA.CEL.gz","hospital: KAR","age: 45","size: 1.6","Surgery_type: 0","Histtype: NA","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 880","e.rfs: 1","t.os: 1924","e.os: 1","t.dmfs: 880","e.dmfs: 1","t.tdm: 880","e.tdm: 1","risksg: 2","NPI: 4.32","risknpi: 2","AOL_os_10y: 84.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178020/suppl/GSM178020.cel.gz","22283","Reanalyzed by: GSE47561","","45","NA","84.3","1","1","1","1","1","136-15D9_KIA.CEL.gz","3","NA","KAR","15D9","NA","0","4.32","1","2","2","VDXKIU_15D9","1.6","0","880","1924","880","880","Poor"
"GSM178021","VDXKIU_15H3","GSM178021","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15H3","Homo sapiens","samplename: VDXKIU_15H3","id: 15H3","filename: 121-15H3_KIA.CEL.gz","hospital: KAR","age: 33","size: 2.8","Surgery_type: 1","Histtype: NA","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 8711","e.rfs: 0","t.os: 8711","e.os: 0","t.dmfs: 8711","e.dmfs: 0","t.tdm: 8711","e.tdm: 0","risksg: 2","NPI: 4.56","risknpi: 2","AOL_os_10y: 68.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178021/suppl/GSM178021.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","33","NA","68.1","0","0","0","0","0","121-15H3_KIA.CEL.gz","3","NA","KAR","15H3","NA","0","4.56","1","2","2","VDXKIU_15H3","2.8","1","8711","8711","8711","8711","Good"
"GSM178022","VDXKIU_15H4","GSM178022","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_15H4","Homo sapiens","samplename: VDXKIU_15H4","id: 15H4","filename: 116-15H4_KIA.CEL.gz","hospital: KAR","age: 37","size: 2.4","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4672","e.rfs: 0","t.os: 4672","e.os: 0","t.dmfs: 4672","e.dmfs: 0","t.tdm: 4672","e.tdm: 0","risksg: 2","NPI: 4.48","risknpi: 2","AOL_os_10y: 67.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178022/suppl/GSM178022.cel.gz","22283","Reanalyzed by: GSE47561","","37","NA","67.9","0","0","0","0","0","116-15H4_KIA.CEL.gz","3","1","KAR","15H4","NA","0","4.48","1","2","2","VDXKIU_15H4","2.4","0","4672","4672","4672","4672","Poor"
"GSM178023","VDXKIU_16B4","GSM178023","Public on Jun 11 2007","Mar 28 2007","Sep 23 2011","RNA","1","VDXKIU_16B4","Homo sapiens","samplename: VDXKIU_16B4","id: 16B4","filename: 111-16B4_KIA.CEL.gz","hospital: KAR","age: 42","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 6943","e.rfs: 0","t.os: 6943","e.os: 0","t.dmfs: 6943","e.dmfs: 0","t.tdm: 6943","e.tdm: 0","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 67.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178023/suppl/GSM178023.cel.gz","22283","Reanalyzed by: GSE31519","","42","NA","67.3","0","0","0","0","0","111-16B4_KIA.CEL.gz","3","1","KAR","16B4","NA","0","4.5","1","2","2","VDXKIU_16B4","2.5","1","6943","6943","6943","6943","Poor"
"GSM178024","VDXKIU_16C8","GSM178024","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_16C8","Homo sapiens","samplename: VDXKIU_16C8","id: 16C8","filename: 122-16C8_KIA.CEL.gz","hospital: KAR","age: 47","size: 1.1","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 6135","e.rfs: 0","t.os: 6135","e.os: 0","t.dmfs: 6135","e.dmfs: 0","t.tdm: 6135","e.tdm: 0","risksg: 2","NPI: 4.22","risknpi: 2","AOL_os_10y: 83.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178024/suppl/GSM178024.cel.gz","22283","Reanalyzed by: GSE47561","","47","NA","83.8","0","0","0","0","1","122-16C8_KIA.CEL.gz","3","1","KAR","16C8","NA","0","4.22","1","2","2","VDXKIU_16C8","1.1","1","6135","6135","6135","6135","Good"
"GSM178025","VDXKIU_16G1","GSM178025","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_16G1","Homo sapiens","samplename: VDXKIU_16G1","id: 16G1","filename: 109-16G1_KIA.CEL.gz","hospital: KAR","age: 43","size: 2","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 805","e.rfs: 1","t.os: 1803","e.os: 1","t.dmfs: 805","e.dmfs: 1","t.tdm: 805","e.tdm: 1","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 89.6","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178025/suppl/GSM178025.cel.gz","22283","Reanalyzed by: GSE47561","","43","NA","89.6","1","1","1","1","1","109-16G1_KIA.CEL.gz","2","1","KAR","16G1","NA","0","3.4","0","2","2","VDXKIU_16G1","2","1","805","1803","805","805","Poor"
"GSM178026","VDXKIU_197B95","GSM178026","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_197B95","Homo sapiens","samplename: VDXKIU_197B95","id: 197B95","filename: 128-197B95_KIA.CEL.gz","hospital: KAR","age: 44","size: 1.6","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5917","e.rfs: 0","t.os: 5917","e.os: 0","t.dmfs: 5917","e.dmfs: 0","t.tdm: 5917","e.tdm: 0","risksg: 2","NPI: 4.32","risknpi: 2","AOL_os_10y: 84.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178026/suppl/GSM178026.cel.gz","22283","Reanalyzed by: GSE47561","","44","NA","84.6","0","0","0","0","1","128-197B95_KIA.CEL.gz","3","1","KAR","197B95","NA","0","4.32","1","2","2","VDXKIU_197B95","1.6","0","5917","5917","5917","5917","Poor"
"GSM178027","VDXKIU_199B55","GSM178027","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_199B55","Homo sapiens","samplename: VDXKIU_199B55","id: 199B55","filename: 110-199B55_KIA.CEL.gz","hospital: KAR","age: 54","size: 2.3","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5909","e.rfs: 0","t.os: 5909","e.os: 0","t.dmfs: 5909","e.dmfs: 0","t.tdm: 5909","e.tdm: 0","risksg: 2","NPI: 3.46","risknpi: 2","AOL_os_10y: 77.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178027/suppl/GSM178027.cel.gz","22283","Reanalyzed by: GSE47561","","54","NA","77.1","0","0","0","0","1","110-199B55_KIA.CEL.gz","2","1","KAR","199B55","NA","0","3.46","1","2","2","VDXKIU_199B55","2.3","1","5909","5909","5909","5909","Good"
"GSM178028","VDXKIU_219C42","GSM178028","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_219C42","Homo sapiens","samplename: VDXKIU_219C42","id: 219C42","filename: 125-219C42_KIA.CEL.gz","hospital: KAR","age: 51","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 2196","e.rfs: 1","t.os: 2196","e.os: 1","t.dmfs: 2196","e.dmfs: 1","t.tdm: 2196","e.tdm: 0","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 81.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178028/suppl/GSM178028.cel.gz","22283","Reanalyzed by: GSE47561","","51","NA","81.4","1","1","1","0","0","125-219C42_KIA.CEL.gz","2","1","KAR","219C42","NA","0","3.36","1","2","2","VDXKIU_219C42","1.8","0","2196","2196","2196","2196","Poor"
"GSM178029","VDXKIU_220C70","GSM178029","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_220C70","Homo sapiens","samplename: VDXKIU_220C70","id: 220C70","filename: 127-220C70_KIA.CEL.gz","hospital: KAR","age: 42","size: 2","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5860","e.rfs: 0","t.os: 5860","e.os: 0","t.dmfs: 5860","e.dmfs: 0","t.tdm: 5860","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 89.8","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178029/suppl/GSM178029.cel.gz","22283","Reanalyzed by: GSE47561","","42","NA","89.8","0","0","0","0","1","127-220C70_KIA.CEL.gz","2","3","KAR","220C70","NA","0","3.4","0","2","2","VDXKIU_220C70","2","0","5860","5860","5860","5860","Poor"
"GSM178030","VDXKIU_231C80","GSM178030","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_231C80","Homo sapiens","samplename: VDXKIU_231C80","id: 231C80","filename: 115-231C80_KIA.CEL.gz","hospital: KAR","age: 56","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 2349","e.rfs: 1","t.os: 3650","e.os: 1","t.dmfs: 2349","e.dmfs: 1","t.tdm: 2349","e.tdm: 1","risksg: 2","NPI: 3.44","risknpi: 2","AOL_os_10y: 76.1","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178030/suppl/GSM178030.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","76.1","1","1","1","1","1","115-231C80_KIA.CEL.gz","2","1","KAR","231C80","NA","0","3.44","1","2","2","VDXKIU_231C80","2.2","0","2349","3650","2349","2349","Good"
"GSM178031","VDXKIU_247C76","GSM178031","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_247C76","Homo sapiens","samplename: VDXKIU_247C76","id: 247C76","filename: 133-247C76_KIA.CEL.gz","hospital: KAR","age: 56","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5779","e.rfs: 0","t.os: 5779","e.os: 0","t.dmfs: 5779","e.dmfs: 0","t.tdm: 5779","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 76.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178031/suppl/GSM178031.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","76.1","0","0","0","0","1","133-247C76_KIA.CEL.gz","2","1","KAR","247C76","NA","0","3.5","1","2","2","VDXKIU_247C76","2.5","0","5779","5779","5779","5779","Poor"
"GSM178032","VDXKIU_248C91","GSM178032","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_248C91","Homo sapiens","samplename: VDXKIU_248C91","id: 248C91","filename: 119-248C91_KIA.CEL.gz","hospital: KAR","age: 58","size: 2.3","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5779","e.rfs: 0","t.os: 5779","e.os: 0","t.dmfs: 5779","e.dmfs: 0","t.tdm: 5779","e.tdm: 0","risksg: 2","NPI: 4.46","risknpi: 2","AOL_os_10y: 68.4","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178032/suppl/GSM178032.cel.gz","22283","Reanalyzed by: GSE47561","","58","NA","68.4","0","0","0","0","1","119-248C91_KIA.CEL.gz","3","3","KAR","248C91","NA","0","4.46","1","2","2","VDXKIU_248C91","2.3","0","5779","5779","5779","5779","Good"
"GSM178033","VDXKIU_266C51","GSM178033","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXKIU_266C51","Homo sapiens","samplename: VDXKIU_266C51","id: 266C51","filename: 205-266C51_KIA.CEL.gz","hospital: KAR","age: 58","size: 2.2","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5723","e.rfs: 0","t.os: 5723","e.os: 0","t.dmfs: 5723","e.dmfs: 0","t.tdm: 5723","e.tdm: 0","risksg: 2","NPI: 3.44","risknpi: 2","AOL_os_10y: 74.8","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178033/suppl/GSM178033.cel.gz","22283","","","58","NA","74.8","0","0","0","0","1","205-266C51_KIA.CEL.gz","2","3","KAR","266C51","NA","0","3.44","1","2","2","VDXKIU_266C51","2.2","0","5723","5723","5723","5723","Good"
"GSM178034","VDXKIU_268C87","GSM178034","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_268C87","Homo sapiens","samplename: VDXKIU_268C87","id: 268C87","filename: 117-268C87_KIA.CEL.gz","hospital: KAR","age: 32","size: 1.5","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5714","e.rfs: 0","t.os: 5714","e.os: 0","t.dmfs: 5714","e.dmfs: 0","t.tdm: 5714","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 87","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178034/suppl/GSM178034.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","32","NA","87","0","0","0","0","1","117-268C87_KIA.CEL.gz","2","3","KAR","268C87","NA","0","3.3","1","1","2","VDXKIU_268C87","1.5","0","5714","5714","5714","5714","Good"
"GSM178035","VDXKIU_279C61","GSM178035","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_279C61","Homo sapiens","samplename: VDXKIU_279C61","id: 279C61","filename: 132-279C61_KIA.CEL.gz","hospital: KAR","age: 50","size: 1.9","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5653","e.rfs: 0","t.os: 5653","e.os: 0","t.dmfs: 5653","e.dmfs: 0","t.tdm: 5653","e.tdm: 0","risksg: 2","NPI: 4.38","risknpi: 2","AOL_os_10y: 82.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178035/suppl/GSM178035.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","50","NA","82.8","0","0","0","0","1","132-279C61_KIA.CEL.gz","3","1","KAR","279C61","NA","0","4.38","1","2","2","VDXKIU_279C61","1.9","1","5653","5653","5653","5653","Poor"
"GSM178036","VDXKIU_27B8","GSM178036","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_27B8","Homo sapiens","samplename: VDXKIU_27B8","id: 27B8","filename: 139-27B8_KIA.CEL.gz","hospital: KAR","age: 49","size: 1.3","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 125","e.rfs: 1","t.os: 146","e.os: 1","t.dmfs: 125","e.dmfs: 1","t.tdm: 125","e.tdm: 1","risksg: 2","NPI: 4.26","risknpi: 2","AOL_os_10y: 79.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178036/suppl/GSM178036.cel.gz","22283","Reanalyzed by: GSE47561","","49","NA","79.3","1","1","1","1","0","139-27B8_KIA.CEL.gz","3","1","KAR","27B8","NA","0","4.26","1","2","2","VDXKIU_27B8","1.3","1","125","146","125","125","Poor"
"GSM178037","VDXKIU_27C4","GSM178037","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_27C4","Homo sapiens","samplename: VDXKIU_27C4","id: 27C4","filename: 235-27C4_KIA.CEL.gz","hospital: KAR","age: 47","size: 1.9","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 5678","e.rfs: 0","t.os: 5678","e.os: 0","t.dmfs: 5678","e.dmfs: 0","t.tdm: 5678","e.tdm: 0","risksg: 1","NPI: 2.38","risknpi: 1","AOL_os_10y: 93.4","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178037/suppl/GSM178037.cel.gz","22283","Reanalyzed by: GSE47561","","47","NA","93.4","0","0","0","0","1","235-27C4_KIA.CEL.gz","1","1","KAR","27C4","NA","0","2.38","0","1","1","VDXKIU_27C4","1.9","0","5678","5678","5678","5678","Poor"
"GSM178038","VDXKIU_27D5","GSM178038","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_27D5","Homo sapiens","samplename: VDXKIU_27D5","id: 27D5","filename: 143-27D5_KIA.CEL.gz","hospital: KAR","age: 56","size: 2.2","Surgery_type: 1","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1742","e.rfs: 1","t.os: 2697","e.os: 1","t.dmfs: 1742","e.dmfs: 1","t.tdm: 1742","e.tdm: 1","risksg: 2","NPI: 3.44","risknpi: 2","AOL_os_10y: 76.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178038/suppl/GSM178038.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","76.1","1","1","1","1","1","143-27D5_KIA.CEL.gz","2","1","KAR","27D5","NA","0","3.44","1","2","2","VDXKIU_27D5","2.2","1","1742","2697","1742","1742","Poor"
"GSM178039","VDXKIU_282C51","GSM178039","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_282C51","Homo sapiens","samplename: VDXKIU_282C51","id: 282C51","filename: 141-282C51_KIA.CEL.gz","hospital: KAR","age: 55","size: 1","Surgery_type: 0","Histtype: 7","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 865","e.rfs: 1","t.os: 3614","e.os: 1","t.dmfs: 3614","e.dmfs: 1","t.tdm: 3614","e.tdm: 0","risksg: 1","NPI: 2.2","risknpi: 1","AOL_os_10y: 91.5","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178039/suppl/GSM178039.cel.gz","22283","Reanalyzed by: GSE47561","","55","NA","91.5","1","1","1","0","1","141-282C51_KIA.CEL.gz","1","7","KAR","282C51","NA","0","2.2","0","1","1","VDXKIU_282C51","1","0","3614","3614","865","3614","Good"
"GSM178040","VDXKIU_284C63","GSM178040","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_284C63","Homo sapiens","samplename: VDXKIU_284C63","id: 284C63","filename: 184-284C63_KIA.CEL.gz","hospital: KAR","age: 48","size: 1.8","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5602","e.rfs: 0","t.os: 5602","e.os: 0","t.dmfs: 5602","e.dmfs: 0","t.tdm: 5602","e.tdm: 0","risksg: 2","NPI: 3.36","risknpi: 2","AOL_os_10y: 88.3","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178040/suppl/GSM178040.cel.gz","22283","Reanalyzed by: GSE47561","","48","NA","88.3","0","0","0","0","1","184-284C63_KIA.CEL.gz","2","1","KAR","284C63","NA","0","3.36","0","2","2","VDXKIU_284C63","1.8","0","5602","5602","5602","5602","Poor"
"GSM178041","VDXKIU_28C76","GSM178041","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_28C76","Homo sapiens","samplename: VDXKIU_28C76","id: 28C76","filename: 114-28C76_KIA.CEL.gz","hospital: KAR","age: 56","size: 0.9","Surgery_type: 0","Histtype: NA","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5768","e.rfs: 0","t.os: 5768","e.os: 0","t.dmfs: 5768","e.dmfs: 0","t.tdm: 5768","e.tdm: 0","risksg: 2","NPI: 3.18","risknpi: 1","AOL_os_10y: 89","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178041/suppl/GSM178041.cel.gz","22283","Reanalyzed by: GSE47561","","56","NA","89","0","0","0","0","1","114-28C76_KIA.CEL.gz","2","NA","KAR","28C76","NA","0","3.18","0","1","2","VDXKIU_28C76","0.9","0","5768","5768","5768","5768","Good"
"GSM178042","VDXKIU_292C66","GSM178042","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_292C66","Homo sapiens","samplename: VDXKIU_292C66","id: 292C66","filename: 137-292C66_KIA.CEL.gz","hospital: KAR","age: 51","size: 2","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5684","e.rfs: 0","t.os: 5684","e.os: 0","t.dmfs: 5684","e.dmfs: 0","t.tdm: 5684","e.tdm: 0","risksg: 2","NPI: 3.4","risknpi: 2","AOL_os_10y: 87.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178042/suppl/GSM178042.cel.gz","22283","Reanalyzed by: GSE47561","","51","NA","87.2","0","0","0","0","1","137-292C66_KIA.CEL.gz","2","3","KAR","292C66","NA","0","3.4","1","2","2","VDXKIU_292C66","2","0","5684","5684","5684","5684","Poor"
"GSM178043","VDXKIU_309C49","GSM178043","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_309C49","Homo sapiens","samplename: VDXKIU_309C49","id: 309C49","filename: 181-309C49_KIA.CEL.gz","hospital: KAR","age: 44","size: 1.2","Surgery_type: 0","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5530","e.rfs: 0","t.os: 5530","e.os: 0","t.dmfs: 5530","e.dmfs: 0","t.tdm: 5530","e.tdm: 0","risksg: 2","NPI: 4.24","risknpi: 2","AOL_os_10y: 84.6","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178043/suppl/GSM178043.cel.gz","22283","Reanalyzed by: GSE47561","","44","NA","84.6","0","0","0","0","1","181-309C49_KIA.CEL.gz","3","3","KAR","309C49","NA","0","4.24","1","2","2","VDXKIU_309C49","1.2","0","5530","5530","5530","5530","Good"
"GSM178044","VDXKIU_43C47","GSM178044","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_43C47","Homo sapiens","samplename: VDXKIU_43C47","id: 43C47","filename: 182-43C47_KIA.CEL.gz","hospital: KAR","age: 46","size: 1.2","Surgery_type: 0","Histtype: 1","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 2","er: 0","t.rfs: 232","e.rfs: 1","t.os: 5551","e.os: 0","t.dmfs: 5551","e.dmfs: 0","t.tdm: 5551","e.tdm: 0","risksg: 2","NPI: 3.24","risknpi: 1","AOL_os_10y: 83.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178044/suppl/GSM178044.cel.gz","22283","Reanalyzed by: GSE47561","","46","NA","83.1","0","0","1","0","0","182-43C47_KIA.CEL.gz","2","1","KAR","43C47","NA","0","3.24","1","1","2","VDXKIU_43C47","1.2","0","5551","5551","232","5551","Poor"
"GSM178045","VDXKIU_87A79","GSM178045","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXKIU_87A79","Homo sapiens","samplename: VDXKIU_87A79","id: 87A79","filename: 237-87A79_KIA.CEL.gz","hospital: KAR","age: 36","size: 1.2","Surgery_type: 1","Histtype: 3","Angioinv: NA","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 6352","e.rfs: 0","t.os: 6352","e.os: 0","t.dmfs: 6352","e.dmfs: 0","t.tdm: 6352","e.tdm: 0","risksg: 1","NPI: 2.24","risknpi: 1","AOL_os_10y: 95.5","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178045/suppl/GSM178045.cel.gz","22283","Reanalyzed by: GSE47561","","36","NA","95.5","0","0","0","0","1","237-87A79_KIA.CEL.gz","1","3","KAR","87A79","NA","0","2.24","0","1","1","VDXKIU_87A79","1.2","1","6352","6352","6352","6352","Poor"
"GSM178046","VDXRHU_302","GSM178046","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_302","Homo sapiens","samplename: VDXRHU_302","id: 302","filename: 155-302_RHA.CEL.gz","hospital: RH","age: 44","size: 1.3","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 722","e.rfs: 1","t.os: 6295","e.os: 0","t.dmfs: 6295","e.dmfs: 0","t.tdm: 6295","e.tdm: 0","risksg: 2","NPI: 3.26","risknpi: 1","AOL_os_10y: 89.4","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178046/suppl/GSM178046.cel.gz","22283","Reanalyzed by: GSE47561","","44","0","89.4","0","0","1","0","1","155-302_RHA.CEL.gz","2","1","RH","302","NA","0","3.26","0","1","2","VDXRHU_302","1.3","0","6295","6295","722","6295","Poor"
"GSM178047","VDXRHU_317","GSM178047","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_317","Homo sapiens","samplename: VDXRHU_317","id: 317","filename: 163-317_RHA.CEL.gz","hospital: RH","age: 41","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 6590","e.rfs: 1","t.os: 7260","e.os: 0","t.dmfs: 7185","e.dmfs: 1","t.tdm: 7185","e.tdm: 1","risksg: 2","NPI: 3.44","risknpi: 2","AOL_os_10y: 81.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178047/suppl/GSM178047.cel.gz","22283","Reanalyzed by: GSE47561","","41","0","81.2","1","0","1","1","1","163-317_RHA.CEL.gz","2","1","RH","317","NA","0","3.44","1","2","2","VDXRHU_317","2.2","0","7185","7260","6590","7185","Poor"
"GSM178048","VDXRHU_329","GSM178048","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXRHU_329","Homo sapiens","samplename: VDXRHU_329","id: 329","filename: 159-329_RHA.CEL.gz","hospital: RH","age: 60","size: 3","Surgery_type: 1","Histtype: 4","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 6281","e.rfs: 0","t.os: 6281","e.os: 0","t.dmfs: 6281","e.dmfs: 0","t.tdm: 6281","e.tdm: 0","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 73.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178048/suppl/GSM178048.cel.gz","22283","","","60","0","73.4","0","0","0","0","1","159-329_RHA.CEL.gz","2","4","RH","329","NA","0","3.6","1","2","2","VDXRHU_329","3","1","6281","6281","6281","6281","Poor"
"GSM178049","VDXRHU_410","GSM178049","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_410","Homo sapiens","samplename: VDXRHU_410","id: 410","filename: 149-410_RHA.CEL.gz","hospital: RH","age: 59","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 3313","e.rfs: 1","t.os: 4594","e.os: 1","t.dmfs: 3313","e.dmfs: 1","t.tdm: 3313","e.tdm: 1","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 74.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178049/suppl/GSM178049.cel.gz","22283","Reanalyzed by: GSE47561","","59","0","74.2","1","1","1","1","1","149-410_RHA.CEL.gz","2","1","RH","410","NA","0","3.6","1","2","2","VDXRHU_410","3","1","3313","4594","3313","3313","Poor"
"GSM178050","VDXRHU_535","GSM178050","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_535","Homo sapiens","samplename: VDXRHU_535","id: 535","filename: 171-535_RHA.CEL.gz","hospital: RH","age: 48","size: 2.7","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 6003","e.rfs: 0","t.os: 6003","e.os: 0","t.dmfs: 6003","e.dmfs: 0","t.tdm: 6003","e.tdm: 0","risksg: 2","NPI: 4.54","risknpi: 2","AOL_os_10y: 66.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178050/suppl/GSM178050.cel.gz","22283","Reanalyzed by: GSE47561","","48","0","66.2","0","0","0","0","0","171-535_RHA.CEL.gz","3","1","RH","535","NA","0","4.54","1","2","2","VDXRHU_535","2.7","0","6003","6003","6003","6003","Poor"
"GSM178051","VDXRHU_1207","GSM178051","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1207","Homo sapiens","samplename: VDXRHU_1207","id: 1207","filename: 152-1207_RHA.CEL.gz","hospital: RH","age: 53","size: 3","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 966","e.rfs: 1","t.os: 2972","e.os: 1","t.dmfs: 2972","e.dmfs: 1","t.tdm: 2972","e.tdm: 0","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 77.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178051/suppl/GSM178051.cel.gz","22283","Reanalyzed by: GSE47561","","53","0","77.7","1","1","1","0","1","152-1207_RHA.CEL.gz","2","1","RH","1207","NA","0","3.6","1","2","2","VDXRHU_1207","3","1","2972","2972","966","2972","Poor"
"GSM178052","VDXRHU_1246","GSM178052","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1246","Homo sapiens","samplename: VDXRHU_1246","id: 1246","filename: 161-1246_RHA.CEL.gz","hospital: RH","age: 43","size: 4","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 6232","e.rfs: 0","t.os: 6232","e.os: 0","t.dmfs: 6232","e.dmfs: 0","t.tdm: 6232","e.tdm: 1","risksg: 2","NPI: 4.8","risknpi: 2","AOL_os_10y: 63.3","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178052/suppl/GSM178052.cel.gz","22283","Reanalyzed by: GSE47561","","43","0","63.3","0","0","0","1","0","161-1246_RHA.CEL.gz","3","1","RH","1246","NA","0","4.8","1","2","2","VDXRHU_1246","4","0","6232","6232","6232","6232","Good"
"GSM178053","VDXRHU_1315","GSM178053","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1315","Homo sapiens","samplename: VDXRHU_1315","id: 1315","filename: 172-1315_RHA.CEL.gz","hospital: RH","age: 33","size: 1.5","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1857","e.rfs: 1","t.os: 9108","e.os: 0","t.dmfs: 9108","e.dmfs: 0","t.tdm: 9108","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 86.9","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178053/suppl/GSM178053.cel.gz","22283","Reanalyzed by: GSE47561","","33","0","86.9","0","0","1","0","1","172-1315_RHA.CEL.gz","2","1","RH","1315","NA","0","3.3","1","1","2","VDXRHU_1315","1.5","0","9108","9108","1857","9108","Poor"
"GSM178054","VDXRHU_1472","GSM178054","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1472","Homo sapiens","samplename: VDXRHU_1472","id: 1472","filename: 162-1472_RHA.CEL.gz","hospital: RH","age: 42","size: 2.6","Surgery_type: 0","Histtype: 2","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 4353","e.rfs: 1","t.os: 5445","e.os: 1","t.dmfs: 4353","e.dmfs: 1","t.tdm: 4353","e.tdm: 1","risksg: 2","NPI: 2.52","risknpi: 1","AOL_os_10y: 88.9","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178054/suppl/GSM178054.cel.gz","22283","Reanalyzed by: GSE47561","","42","0","88.9","1","1","1","1","1","162-1472_RHA.CEL.gz","1","2","RH","1472","NA","0","2.52","0","1","2","VDXRHU_1472","2.6","0","4353","5445","4353","4353","Good"
"GSM178055","VDXRHU_1496","GSM178055","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1496","Homo sapiens","samplename: VDXRHU_1496","id: 1496","filename: 177-1496_RHA.CEL.gz","hospital: RH","age: 51","size: 4","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 3914","e.rfs: 0","t.os: 3914","e.os: 0","t.dmfs: 3914","e.dmfs: 0","t.tdm: 3914","e.tdm: 0","risksg: 2","NPI: 4.8","risknpi: 2","AOL_os_10y: 61.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178055/suppl/GSM178055.cel.gz","22283","Reanalyzed by: GSE47561","","51","0","61.5","0","0","0","0","0","177-1496_RHA.CEL.gz","3","1","RH","1496","NA","0","4.8","1","2","2","VDXRHU_1496","4","1","3914","3914","3914","3914","Poor"
"GSM178056","VDXRHU_1522","GSM178056","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1522","Homo sapiens","samplename: VDXRHU_1522","id: 1522","filename: 156-1522_RHA.CEL.gz","hospital: RH","age: 31","size: 1.7","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5181","e.rfs: 0","t.os: 5181","e.os: 0","t.dmfs: 5181","e.dmfs: 0","t.tdm: 5181","e.tdm: 0","risksg: 2","NPI: 4.34","risknpi: 2","AOL_os_10y: 80.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178056/suppl/GSM178056.cel.gz","22283","Reanalyzed by: GSE47561","","31","0","80.1","0","0","0","0","1","156-1522_RHA.CEL.gz","3","1","RH","1522","NA","0","4.34","1","2","2","VDXRHU_1522","1.7","0","5181","5181","5181","5181","Poor"
"GSM178057","VDXRHU_1526","GSM178057","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1526","Homo sapiens","samplename: VDXRHU_1526","id: 1526","filename: 174-1526_RHA.CEL.gz","hospital: RH","age: 60","size: 3.2","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 3855","e.rfs: 0","t.os: 3855","e.os: 0","t.dmfs: 3855","e.dmfs: 0","t.tdm: 3855","e.tdm: 0","risksg: 2","NPI: 4.64","risknpi: 2","AOL_os_10y: 59.9","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178057/suppl/GSM178057.cel.gz","22283","Reanalyzed by: GSE47561","","60","0","59.9","0","0","0","0","1","174-1526_RHA.CEL.gz","3","1","RH","1526","NA","0","4.64","1","2","2","VDXRHU_1526","3.2","1","3855","3855","3855","3855","Good"
"GSM178058","VDXRHU_1549","GSM178058","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1549","Homo sapiens","samplename: VDXRHU_1549","id: 1549","filename: 158-1549_RHA.CEL.gz","hospital: RH","age: 46","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 5156","e.rfs: 0","t.os: 5156","e.os: 0","t.dmfs: 5156","e.dmfs: 0","t.tdm: 5156","e.tdm: 0","risksg: 2","NPI: 4.4","risknpi: 2","AOL_os_10y: 84.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178058/suppl/GSM178058.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","46","0","84.1","0","0","0","0","1","158-1549_RHA.CEL.gz","3","1","RH","1549","NA","0","4.4","1","2","2","VDXRHU_1549","2","0","5156","5156","5156","5156","Poor"
"GSM178059","VDXRHU_1568","GSM178059","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1568","Homo sapiens","samplename: VDXRHU_1568","id: 1568","filename: 167-1568_RHA.CEL.gz","hospital: RH","age: 59","size: 2.1","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4744","e.rfs: 0","t.os: 4744","e.os: 0","t.dmfs: 4744","e.dmfs: 0","t.tdm: 4744","e.tdm: 0","risksg: 2","NPI: 4.42","risknpi: 2","AOL_os_10y: 61.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178059/suppl/GSM178059.cel.gz","22283","Reanalyzed by: GSE47561","","59","0","61.5","0","0","0","0","0","167-1568_RHA.CEL.gz","3","1","RH","1568","NA","0","4.42","1","2","2","VDXRHU_1568","2.1","0","4744","4744","4744","4744","Poor"
"GSM178060","VDXRHU_1720","GSM178060","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1720","Homo sapiens","samplename: VDXRHU_1720","id: 1720","filename: 165-1720_RHA.CEL.gz","hospital: RH","age: 24","size: 3.2","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 794","e.rfs: 1","t.os: 1308","e.os: 1","t.dmfs: 794","e.dmfs: 1","t.tdm: 794","e.tdm: 1","risksg: 2","NPI: 2.64","risknpi: 1","AOL_os_10y: 79.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178060/suppl/GSM178060.cel.gz","22283","Reanalyzed by: GSE47561","","24","1","79.5","1","1","1","1","1","165-1720_RHA.CEL.gz","1","1","RH","1720","NA","0","2.64","1","1","2","VDXRHU_1720","3.2","0","794","1308","794","794","Poor"
"GSM178061","VDXRHU_1721","GSM178061","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1721","Homo sapiens","samplename: VDXRHU_1721","id: 1721","filename: 221-1721_RHA.CEL.gz","hospital: RH","age: 54","size: 3","Surgery_type: 1","Histtype: 0","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1598","e.rfs: 1","t.os: 1864","e.os: 1","t.dmfs: 1598","e.dmfs: 1","t.tdm: 1598","e.tdm: 1","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 77.1","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178061/suppl/GSM178061.cel.gz","22283","Reanalyzed by: GSE47561","","54","1","77.1","1","1","1","1","1","221-1721_RHA.CEL.gz","2","0","RH","1721","NA","0","3.6","1","2","2","VDXRHU_1721","3","1","1598","1864","1598","1598","Poor"
"GSM178062","VDXRHU_1745","GSM178062","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1745","Homo sapiens","samplename: VDXRHU_1745","id: 1745","filename: 170-1745_RHA.CEL.gz","hospital: RH","age: 55","size: 0.8","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5038","e.rfs: 0","t.os: 5038","e.os: 0","t.dmfs: 5038","e.dmfs: 0","t.tdm: 5038","e.tdm: 0","risksg: 2","NPI: 3.16","risknpi: 1","AOL_os_10y: 89.7","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178062/suppl/GSM178062.cel.gz","22283","Reanalyzed by: GSE47561","","55","0","89.7","0","0","0","0","1","170-1745_RHA.CEL.gz","2","1","RH","1745","NA","0","3.16","0","1","2","VDXRHU_1745","0.8","0","5038","5038","5038","5038","Poor"
"GSM178063","VDXRHU_1767","GSM178063","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1767","Homo sapiens","samplename: VDXRHU_1767","id: 1767","filename: 223-1767_RHA.CEL.gz","hospital: RH","age: 41","size: 2.1","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4874","e.rfs: 0","t.os: 4874","e.os: 0","t.dmfs: 4874","e.dmfs: 0","t.tdm: 4874","e.tdm: 0","risksg: 2","NPI: 4.42","risknpi: 2","AOL_os_10y: 67.5","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178063/suppl/GSM178063.cel.gz","22283","Reanalyzed by: GSE47561","","41","1","67.5","0","0","0","0","0","223-1767_RHA.CEL.gz","3","1","RH","1767","NA","0","4.42","1","2","2","VDXRHU_1767","2.1","0","4874","4874","4874","4874","Poor"
"GSM178064","VDXRHU_1771","GSM178064","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1771","Homo sapiens","samplename: VDXRHU_1771","id: 1771","filename: 226-1771_RHA.CEL.gz","hospital: RH","age: 42","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 4555","e.rfs: 0","t.os: 4555","e.os: 0","t.dmfs: 4555","e.dmfs: 0","t.tdm: 4555","e.tdm: 0","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 74.2","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178064/suppl/GSM178064.cel.gz","22283","Reanalyzed by: GSE47561","","42","0","74.2","0","0","0","0","1","226-1771_RHA.CEL.gz","3","1","RH","1771","NA","0","4.5","1","2","2","VDXRHU_1771","2.5","0","4555","4555","4555","4555","Poor"
"GSM178065","VDXRHU_1917","GSM178065","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1917","Homo sapiens","samplename: VDXRHU_1917","id: 1917","filename: 160-1917_RHA.CEL.gz","hospital: RH","age: 47","size: 2.5","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4487","e.rfs: 0","t.os: 4487","e.os: 0","t.dmfs: 4487","e.dmfs: 0","t.tdm: 4487","e.tdm: 0","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 66.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178065/suppl/GSM178065.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","47","0","66.4","0","0","0","0","0","160-1917_RHA.CEL.gz","3","1","RH","1917","NA","0","4.5","1","2","2","VDXRHU_1917","2.5","1","4487","4487","4487","4487","Poor"
"GSM178066","VDXRHU_1919","GSM178066","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1919","Homo sapiens","samplename: VDXRHU_1919","id: 1919","filename: 168-1919_RHA.CEL.gz","hospital: RH","age: 53","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 4297","e.rfs: 0","t.os: 4297","e.os: 0","t.dmfs: 4297","e.dmfs: 0","t.tdm: 4297","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 64.5","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178066/suppl/GSM178066.cel.gz","22283","Reanalyzed by: GSE47561","","53","0","64.5","0","0","0","0","0","168-1919_RHA.CEL.gz","3","1","RH","1919","NA","0","4.44","1","2","2","VDXRHU_1919","2.2","0","4297","4297","4297","4297","Good"
"GSM178067","VDXRHU_1959","GSM178067","Public on Jun 11 2007","Mar 28 2007","Jun 11 2007","RNA","1","VDXRHU_1959","Homo sapiens","samplename: VDXRHU_1959","id: 1959","filename: 216-1959_RHA.CEL.gz","hospital: RH","age: 50","size: 2.4","Surgery_type: 1","Histtype: 2","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 4866","e.rfs: 0","t.os: 4866","e.os: 0","t.dmfs: 4866","e.dmfs: 0","t.tdm: 4866","e.tdm: 0","risksg: 2","NPI: 3.48","risknpi: 2","AOL_os_10y: 79","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178067/suppl/GSM178067.cel.gz","22283","","","50","0","79","0","0","0","0","1","216-1959_RHA.CEL.gz","2","2","RH","1959","NA","0","3.48","1","2","2","VDXRHU_1959","2.4","1","4866","4866","4866","4866","Poor"
"GSM178068","VDXRHU_1970","GSM178068","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_1970","Homo sapiens","samplename: VDXRHU_1970","id: 1970","filename: 151-1970_RHA.CEL.gz","hospital: RH","age: 44","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 4178","e.rfs: 0","t.os: 4178","e.os: 0","t.dmfs: 4178","e.dmfs: 0","t.tdm: 4178","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 73.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178068/suppl/GSM178068.cel.gz","22283","Reanalyzed by: GSE47561","","44","0","73.8","0","0","0","0","1","151-1970_RHA.CEL.gz","3","1","RH","1970","NA","0","4.44","1","2","2","VDXRHU_1970","2.2","0","4178","4178","4178","4178","Poor"
"GSM178069","VDXRHU_2039","GSM178069","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_2039","Homo sapiens","samplename: VDXRHU_2039","id: 2039","filename: 173-2039_RHA.CEL.gz","hospital: RH","age: 48","size: 1.5","Surgery_type: 0","Histtype: 9","Angioinv: 0","Lymp_infil: 1","node: 0","grade: 1","er: 0","t.rfs: 2674","e.rfs: 1","t.os: 6011","e.os: 1","t.dmfs: 4618","e.dmfs: 1","t.tdm: 4618","e.tdm: 1","risksg: 2","NPI: 2.3","risknpi: 1","AOL_os_10y: 90.3","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178069/suppl/GSM178069.cel.gz","22283","Reanalyzed by: GSE47561","","48","0","90.3","1","1","1","1","0","173-2039_RHA.CEL.gz","1","9","RH","2039","1","0","2.3","1","1","2","VDXRHU_2039","1.5","0","4618","6011","2674","4618","Poor"
"GSM178070","VDXRHU_2248","GSM178070","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_2248","Homo sapiens","samplename: VDXRHU_2248","id: 2248","filename: 150-2248_RHA.CEL.gz","hospital: RH","age: 49","size: 3","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 2541","e.rfs: 1","t.os: 4052","e.os: 0","t.dmfs: 4052","e.dmfs: 0","t.tdm: 4052","e.tdm: 0","risksg: 2","NPI: 3.6","risknpi: 2","AOL_os_10y: 79.3","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178070/suppl/GSM178070.cel.gz","22283","Reanalyzed by: GSE47561","","49","0","79.3","0","0","1","0","1","150-2248_RHA.CEL.gz","2","1","RH","2248","NA","0","3.6","1","2","2","VDXRHU_2248","3","0","4052","4052","2541","4052","Good"
"GSM178071","VDXRHU_2320","GSM178071","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_2320","Homo sapiens","samplename: VDXRHU_2320","id: 2320","filename: 191-2320_RHA.CEL.gz","hospital: RH","age: 43","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 1432","e.rfs: 1","t.os: 3782","e.os: 0","t.dmfs: 3782","e.dmfs: 0","t.tdm: 3782","e.tdm: 0","risksg: 2","NPI: 3.5","risknpi: 2","AOL_os_10y: 80.8","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178071/suppl/GSM178071.cel.gz","22283","Reanalyzed by: GSE47561","","43","0","80.8","0","0","1","0","1","191-2320_RHA.CEL.gz","2","1","RH","2320","NA","0","3.5","1","2","2","VDXRHU_2320","2.5","0","3782","3782","1432","3782","Poor"
"GSM178072","VDXRHU_2393","GSM178072","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_2393","Homo sapiens","samplename: VDXRHU_2393","id: 2393","filename: 148-2393_RHA.CEL.gz","hospital: RH","age: 45","size: 2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 3492","e.rfs: 0","t.os: 3492","e.os: 0","t.dmfs: 3492","e.dmfs: 0","t.tdm: 3492","e.tdm: 0","risksg: 1","NPI: 2.4","risknpi: 1","AOL_os_10y: 94","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178072/suppl/GSM178072.cel.gz","22283","Reanalyzed by: GSE47561","","45","0","94","0","0","0","0","1","148-2393_RHA.CEL.gz","1","1","RH","2393","NA","0","2.4","0","1","1","VDXRHU_2393","2","0","3492","3492","3492","3492","Poor"
"GSM178073","VDXRHU_2587","GSM178073","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_2587","Homo sapiens","samplename: VDXRHU_2587","id: 2587","filename: 157-2587_RHA.CEL.gz","hospital: RH","age: 53","size: 1.4","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 2561","e.rfs: 0","t.os: 2561","e.os: 0","t.dmfs: 2561","e.dmfs: 0","t.tdm: 2561","e.tdm: 0","risksg: 2","NPI: 4.28","risknpi: 2","AOL_os_10y: 77.7","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178073/suppl/GSM178073.cel.gz","22283","Reanalyzed by: GSE47561","","53","0","77.7","0","0","0","0","0","157-2587_RHA.CEL.gz","3","1","RH","2587","NA","0","4.28","1","2","2","VDXRHU_2587","1.4","1","2561","2561","2561","2561","Good"
"GSM178074","VDXRHU_3642","GSM178074","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_3642","Homo sapiens","samplename: VDXRHU_3642","id: 3642","filename: 194-3642_RHA.CEL.gz","hospital: RH","age: 40","size: 4.2","Surgery_type: 0","Histtype: 4","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 1","t.rfs: 2454","e.rfs: 1","t.os: 5284","e.os: 1","t.dmfs: 2454","e.dmfs: 1","t.tdm: 2454","e.tdm: 1","risksg: 2","NPI: 4.84","risknpi: 2","AOL_os_10y: 66.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178074/suppl/GSM178074.cel.gz","22283","Reanalyzed by: GSE47561","","40","0","66.6","1","1","1","1","1","194-3642_RHA.CEL.gz","3","4","RH","3642","NA","0","4.84","1","2","2","VDXRHU_3642","4.2","0","2454","5284","2454","2454","Poor"
"GSM178075","VDXRHU_4188","GSM178075","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_4188","Homo sapiens","samplename: VDXRHU_4188","id: 4188","filename: 176-4188_RHA.CEL.gz","hospital: RH","age: 48","size: 3.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 2879","e.rfs: 0","t.os: 2879","e.os: 0","t.dmfs: 2879","e.dmfs: 0","t.tdm: 2879","e.tdm: 0","risksg: 2","NPI: 4.64","risknpi: 2","AOL_os_10y: 62.3","risk_AOL: 1","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178075/suppl/GSM178075.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","48","0","62.3","0","0","0","0","0","176-4188_RHA.CEL.gz","3","1","RH","4188","NA","0","4.64","1","2","2","VDXRHU_4188","3.2","0","2879","2879","2879","2879","Good"
"GSM178076","VDXRHU_5223","GSM178076","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5223","Homo sapiens","samplename: VDXRHU_5223","id: 5223","filename: 175-5223_RHA.CEL.gz","hospital: RH","age: 56","size: 1.5","Surgery_type: 1","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 5137","e.rfs: 0","t.os: 5137","e.os: 0","t.dmfs: 5137","e.dmfs: 0","t.tdm: 5137","e.tdm: 0","risksg: 2","NPI: 3.3","risknpi: 1","AOL_os_10y: 84.4","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178076/suppl/GSM178076.cel.gz","22283","Reanalyzed by: GSE47561","","56","0","84.4","0","0","0","0","1","175-5223_RHA.CEL.gz","2","1","RH","5223","NA","0","3.3","1","1","2","VDXRHU_5223","1.5","1","5137","5137","5137","5137","Poor"
"GSM178077","VDXRHU_5226","GSM178077","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5226","Homo sapiens","samplename: VDXRHU_5226","id: 5226","filename: 198-5226_RHA.CEL.gz","hospital: RH","age: 45","size: 1.7","Surgery_type: 0","Histtype: 2","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 6961","e.rfs: 1","t.os: 7023","e.os: 0","t.dmfs: 7023","e.dmfs: 0","t.tdm: 7023","e.tdm: 0","risksg: 2","NPI: 3.34","risknpi: 2","AOL_os_10y: 89.2","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178077/suppl/GSM178077.cel.gz","22283","Reanalyzed by: GSE47561","","45","0","89.2","0","0","1","0","1","198-5226_RHA.CEL.gz","2","2","RH","5226","NA","0","3.34","0","2","2","VDXRHU_5226","1.7","0","7023","7023","6961","7023","Poor"
"GSM178078","VDXRHU_5228","GSM178078","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5228","Homo sapiens","samplename: VDXRHU_5228","id: 5228","filename: 164-5228_RHA.CEL.gz","hospital: RH","age: 39","size: 2.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 5673","e.rfs: 0","t.os: 5673","e.os: 0","t.dmfs: 5673","e.dmfs: 0","t.tdm: 5673","e.tdm: 0","risksg: 2","NPI: 4.44","risknpi: 2","AOL_os_10y: 67.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178078/suppl/GSM178078.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","39","0","67.7","0","0","0","0","0","164-5228_RHA.CEL.gz","3","1","RH","5228","NA","0","4.44","1","2","2","VDXRHU_5228","2.2","0","5673","5673","5673","5673","Poor"
"GSM178079","VDXRHU_5232","GSM178079","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5232","Homo sapiens","samplename: VDXRHU_5232","id: 5232","filename: 236-5232_RHA.CEL.gz","hospital: RH","age: 46","size: 3.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 404","e.rfs: 1","t.os: 1246","e.os: 1","t.dmfs: 404","e.dmfs: 1","t.tdm: 404","e.tdm: 1","risksg: 2","NPI: 4.64","risknpi: 2","AOL_os_10y: 62.7","risk_AOL: 0","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178079/suppl/GSM178079.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","46","0","62.7","1","1","1","1","0","236-5232_RHA.CEL.gz","3","1","RH","5232","NA","0","4.64","0","2","2","VDXRHU_5232","3.2","0","404","1246","404","404","Poor"
"GSM178080","VDXRHU_5235","GSM178080","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5235","Homo sapiens","samplename: VDXRHU_5235","id: 5235","filename: 195-5235_RHA.CEL.gz","hospital: RH","age: 47","size: 2.5","Surgery_type: 0","Histtype: 1","Angioinv: 1","Lymp_infil: NA","node: 0","grade: 1","er: 1","t.rfs: 2225","e.rfs: 0","t.os: 2225","e.os: 0","t.dmfs: 2225","e.dmfs: 0","t.tdm: 2225","e.tdm: 0","risksg: 2","NPI: 2.5","risknpi: 1","AOL_os_10y: 87.6","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178080/suppl/GSM178080.cel.gz","22283","Reanalyzed by: GSE47561","","47","1","87.6","0","0","0","0","1","195-5235_RHA.CEL.gz","1","1","RH","5235","NA","0","2.5","1","1","2","VDXRHU_5235","2.5","0","2225","2225","2225","2225","Poor"
"GSM178081","VDXRHU_5236","GSM178081","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5236","Homo sapiens","samplename: VDXRHU_5236","id: 5236","filename: 204-5236_RHA.CEL.gz","hospital: RH","age: 43","size: 1.2","Surgery_type: 0","Histtype: 1","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 2","er: 1","t.rfs: 2722","e.rfs: 0","t.os: 2722","e.os: 0","t.dmfs: 2722","e.dmfs: 0","t.tdm: 2722","e.tdm: 0","risksg: 2","NPI: 3.24","risknpi: 1","AOL_os_10y: 89.6","risk_AOL: 0","veridex_risk: Good","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178081/suppl/GSM178081.cel.gz","22283","Reanalyzed by: GSE47561","","43","0","89.6","0","0","0","0","1","204-5236_RHA.CEL.gz","2","1","RH","5236","NA","0","3.24","0","1","2","VDXRHU_5236","1.2","0","2722","2722","2722","2722","Good"
"GSM178082","VDXRHU_5240","GSM178082","Public on Jun 11 2007","Mar 28 2007","May 31 2013","RNA","1","VDXRHU_5240","Homo sapiens","samplename: VDXRHU_5240","id: 5240","filename: 154-5240_RHA.CEL.gz","hospital: RH","age: 39","size: 2.5","Surgery_type: 0","Histtype: 9","Angioinv: 0","Lymp_infil: NA","node: 0","grade: 3","er: 0","t.rfs: 1345","e.rfs: 1","t.os: 1781","e.os: 0","t.dmfs: 1781","e.dmfs: 0","t.tdm: 1781","e.tdm: 0","risksg: 2","NPI: 4.5","risknpi: 2","AOL_os_10y: 67.7","risk_AOL: 1","veridex_risk: Poor","total RNA","Isolation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc)olation of RNA was performed using the Trizol method (Invitrogen) according to the manufacturers instructions and was purified using RNeasy mini-columns (Qiagen, Valencia, CA). The quality of the RNA obtained from each tumour sample was assessed based on the RNA profile generated by the bioanalyzer (Agilent Inc).","biotin","Approximately 1 microgram of total RNA was processed to produce biotinylated cRNA targets.","9606","standard Affymetrix procedures.","standard Affymetrix procedures.","n/a","MAS5 Bioconductor (target value of 600).","GPL96","Benjamin,,Haibe-Kains","benjamin.haibe.kains@utoronto.ca","+14165818626","Bioinformatics and Computational Genomics","Princess Margaret Research","Princess Margaret Cancer Centre","610 University Avenue","Toronto","Ontario","M5G 2M9","Canada","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM178nnn/GSM178082/suppl/GSM178082.cel.gz","22283","Reanalyzed by: GSE31519","Reanalyzed by: GSE47561","39","0","67.7","0","0","1","0","0","154-5240_RHA.CEL.gz","3","9","RH","5240","NA","0","4.5","1","2","2","VDXRHU_5240","2.5","0","1781","1781","1345","1781","Poor"
